{
    "items": "161",
    "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
    "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
    "feed": [
        {
            "title": "Cancer-causing chemical can form at 'unacceptably high levels' in certain acne products, independent lab claims",
            "url": "https://www.cnn.com/2024/03/06/health/benzene-acne-products-valisure/index.html",
            "time_published": "20240306T233133",
            "authors": [
                "Jacqueline Howard"
            ],
            "summary": "High levels of benzene, a cancer-causing chemical, can form in acne treatment products containing benzoyl peroxide, according to a new report from Valisure, an independent laboratory.",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/210714221158-johnson-and-johnson-sunscreens.jpg?q=x_0,y_5,h_900,w_1600,c_crop/h_144,w_256",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.061573,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.081552",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.040829",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "He Got 49 COVID Shots in One Month!",
            "url": "https://www.theatlantic.com/health/archive/2024/03/217-covid-shots-hypervaccination-study/677666/",
            "time_published": "20240306T213600",
            "authors": [
                "Jacob Stern"
            ],
            "summary": "On June 3, 2021, a roughly 60-year-old man in the riverside city of Magdeburg, Germany, received his first COVID vaccine. He opted for Johnson & Johnson's shot, popular at that point because unlike Pfizer's and Moderna's vaccines, it was one-and-done. But that, evidently, was not what he had in ...",
            "banner_image": "https://cdn.theatlantic.com/thumbor/PXP2_01C3dKolU9Hi6bRPrc8L10=/0x0:2000x1125/960x540/media/img/mt/2024/03/217_shots/original.jpg",
            "source": "The Atlantic",
            "category_within_source": "n/a",
            "source_domain": "www.theatlantic.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.026119,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NYT",
                    "relevance_score": "0.042346",
                    "ticker_sentiment_score": "0.032002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.042346",
                    "ticker_sentiment_score": "0.032002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.126561",
                    "ticker_sentiment_score": "0.049657",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.126561",
                    "ticker_sentiment_score": "0.025729",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.042346",
                    "ticker_sentiment_score": "0.032002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.042346",
                    "ticker_sentiment_score": "0.032002",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ambrx Shareholders Approve Acquisition by Johnson & Johnson - Ambrx Biopharma  ( NASDAQ:AMAM ) ",
            "url": "https://www.benzinga.com/pressreleases/24/03/g37517010/ambrx-shareholders-approve-acquisition-by-johnson-johnson",
            "time_published": "20240306T182000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "SAN DIEGO, March 06, 2024 ( GLOBE NEWSWIRE ) -- Ambrx Biopharma, Inc., ( \"Ambrx\" or the \"Company\" ) AMAM, today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "Mergers",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.184662,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AMAM",
                    "relevance_score": "0.145437",
                    "ticker_sentiment_score": "0.1798",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.097259",
                    "ticker_sentiment_score": "0.266488",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Ambrx Shareholders Approve Acquisition by Johnson & Johnson",
            "url": "https://www.globenewswire.com/news-release/2024/03/06/2841709/0/en/Ambrx-Shareholders-Approve-Acquisition-by-Johnson-Johnson.html",
            "time_published": "20240306T182000",
            "authors": [
                "Ambrx Biopharma Inc."
            ],
            "summary": "SAN DIEGO, March 06, 2024 ( GLOBE NEWSWIRE ) -- Ambrx Biopharma, Inc., ( \"Ambrx\" or the \"Company\" ) ( NASDAQ: AMAM ) , today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/4983c39d-12ad-4feb-81fa-fb6d5d6ee6f1",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.191919,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AMAM",
                    "relevance_score": "0.101797",
                    "ticker_sentiment_score": "0.183311",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.101797",
                    "ticker_sentiment_score": "0.273097",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Encephalitis Treatment Market Overview 2024-2028: Expected Market Size, Major Growth Factors And Lucrative Segments As Per The Business Research Company's Encephalitis Treatment Global Market Report 2024",
            "url": "https://www.benzinga.com/pressreleases/24/03/g37514086/encephalitis-treatment-market-overview-2024-2028-expected-market-size-major-growth-factors-and-luc",
            "time_published": "20240306T163000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "LONDON, March 06, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's encephalitis treatment global market report 2024, the encephalitis treatment market has exhibited robust growth in recent years, with a notable increase in market size.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.3086,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PFE",
                    "relevance_score": "0.117486",
                    "ticker_sentiment_score": "0.19606",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.058903",
                    "ticker_sentiment_score": "0.174004",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.058903",
                    "ticker_sentiment_score": "0.174004",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Chemical linked to cancer found in acne treatment creams including Proactiv | World News",
            "url": "https://www.business-standard.com/world-news/chemical-linked-to-cancer-found-in-acne-treatment-creams-including-proactiv-124030601181_1.html",
            "time_published": "20240306T161543",
            "authors": [
                "Bloomberg"
            ],
            "summary": "Chemical linked to cancer found in acne treatment creams including Proactiv Business Standard ...",
            "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-03/06/full/1709741581-9032.png?im=Resize=(640,480)",
            "source": "Business Standard",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.business-standard.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.052076,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "TARO",
                    "relevance_score": "0.03798",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.03798",
                    "ticker_sentiment_score": "-0.018641",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.03798",
                    "ticker_sentiment_score": "-0.018641",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RBGPF",
                    "relevance_score": "0.03798",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UL",
                    "relevance_score": "0.075874",
                    "ticker_sentiment_score": "-0.060062",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson  ( JNJ )  Is a Trending Stock: Facts to Know Before Betting on It",
            "url": "https://www.zacks.com/stock/news/2236576/johnson-johnson-jnj-is-a-trending-stock-facts-to-know-before-betting-on-it",
            "time_published": "20240306T140014",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default358.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999999"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.5855"
                }
            ],
            "overall_sentiment_score": 0.233293,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.478494",
                    "ticker_sentiment_score": "0.151501",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "A man deliberately got 217 Covid shots. Here's what happened",
            "url": "https://www.cnn.com/2024/03/06/health/covid-217-shots-hypervaccination-lancet/index.html",
            "time_published": "20240306T111100",
            "authors": [
                "Mira Cheng"
            ],
            "summary": "One German man has redefined \"man on a mission.\" A 62-year-old from Magdeburg deliberately got 217 Covid-19 vaccine shots in the span of 29 months, according to a new study, going against national vaccine recommendations. That's an average of one jab every four days.",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231002112056-04-mrna-vaccine-technology-explainer-shot.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.083586,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.069798",
                    "ticker_sentiment_score": "-0.018145",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.034933",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.034933",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BNTX",
                    "relevance_score": "0.034933",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.034933",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.034933",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic - AstraZeneca  ( NASDAQ:AZN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
            "url": "https://www.benzinga.com/news/24/03/37495723/bidens-state-of-the-union-grading-his-results-on-abortion-access-drug-prices-and-opium-epidemic",
            "time_published": "20240305T214503",
            "authors": [
                "Natan Ponieman"
            ],
            "summary": "As President Joe Biden prepares for his State of the Union address on Thursday, he's expected to touch on several key issues including Bidenomics, access to healthcare and the U.S.' role in the world.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/joe-biden-shutter4_9.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.140317,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVS",
                    "relevance_score": "0.121343",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.121343",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.121343",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.121343",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.121343",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Smart Money Is Betting Big In JNJ Options - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/insights/options/24/03/37490074/smart-money-is-betting-big-in-jnj-options",
            "time_published": "20240305T181747",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Financial giants have made a conspicuous bullish move on Johnson & Johnson. Our analysis of options history for Johnson & Johnson JNJ revealed 12 unusual trades. Delving into the details, we found 75% of traders were bullish, while 25% showed bearish tendencies.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                }
            ],
            "overall_sentiment_score": 0.150829,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.082677",
                    "ticker_sentiment_score": "0.142177",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.700759",
                    "ticker_sentiment_score": "0.35771",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "BDA Receives Best Place to Work Recognition by The Sports Business Journal",
            "url": "https://www.prnewswire.com/news-releases/bda-receives-best-place-to-work-recognition-by-the-sports-business-journal-302077238.html",
            "time_published": "20240305T140000",
            "authors": [
                "LLC",
                "Bensussen Deutsch & Associates"
            ],
            "summary": "Global Merchandising Agency Earns Medalist Honors for Outstanding Leadership and Commitment to Employee Satisfaction",
            "banner_image": "https://mma.prnewswire.com/media/2142284/BDA_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.520012,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "FDX",
                    "relevance_score": "0.06515",
                    "ticker_sentiment_score": "0.191432",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HD",
                    "relevance_score": "0.06515",
                    "ticker_sentiment_score": "0.191432",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ICNB",
                    "relevance_score": "0.129866",
                    "ticker_sentiment_score": "0.226214",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.06515",
                    "ticker_sentiment_score": "0.191432",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:EUR",
                    "relevance_score": "0.06515",
                    "ticker_sentiment_score": "0.118167",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Major shareholder announcement - AIM International Mutual Funds",
            "url": "https://www.globenewswire.com/news-release/2024/03/05/2840228/0/en/Major-shareholder-announcement-AIM-International-Mutual-Funds.html",
            "time_published": "20240305T110100",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.124283,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.552443",
                    "ticker_sentiment_score": "0.262306",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.295867",
                    "ticker_sentiment_score": "0.086705",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.295867",
                    "ticker_sentiment_score": "0.086705",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.295867",
                    "ticker_sentiment_score": "0.086705",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Major shareholder announcement - Invesco Ltd.",
            "url": "https://www.globenewswire.com/news-release/2024/03/05/2840224/0/en/Major-shareholder-announcement-Invesco-Ltd.html",
            "time_published": "20240305T110000",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.041462,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.608634",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.331765",
                    "ticker_sentiment_score": "0.094969",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.331765",
                    "ticker_sentiment_score": "0.094969",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.331765",
                    "ticker_sentiment_score": "0.094969",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Big businesses hit with management idea drought",
            "url": "https://www.moneycontrol.com/news/opinion/big-businesses-hit-with-management-idea-drought-12404311.html",
            "time_published": "20240305T073425",
            "authors": [],
            "summary": "The multibillion-dollar industry has lost the intellectual momentum and edge. There are only so many ideas that you can have about managing people or resources, and many of the best were generated long ago ...",
            "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/12/china-yuan-378x213.jpg?impolicy=website&width=168&height=118",
            "source": "Money Control",
            "category_within_source": "Business",
            "source_domain": "www.moneycontrol.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.09896,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GM",
                    "relevance_score": "0.091977",
                    "ticker_sentiment_score": "0.041408",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.03072",
                    "ticker_sentiment_score": "0.070542",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Sandoz announces nominations to the Board of Directors and leadership change",
            "url": "https://www.globenewswire.com/news-release/2024/03/05/2840074/0/en/Sandoz-announces-nominations-to-the-Board-of-Directors-and-leadership-change.html",
            "time_published": "20240305T060000",
            "authors": [
                "Sandoz International GmbH"
            ],
            "summary": "Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/41ea40f9-fbb7-45d9-9136-33fdb399d0ba",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.181593,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AOMFF",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "0.002006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TXG",
                    "relevance_score": "0.03399",
                    "ticker_sentiment_score": "0.004778",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.03399",
                    "ticker_sentiment_score": "0.004778",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Sandoz announces nominations to the Board of Directors and leadership change",
            "url": "https://markets.businessinsider.com/news/stocks/sandoz-announces-nominations-to-the-board-of-directors-and-leadership-change-1033131130",
            "time_published": "20240305T060000",
            "authors": [
                "markets.businessinsider.com"
            ],
            "summary": "• Mathai Mammen and Michael Rechsteiner nominated to stand for election to Sandoz Board of Directors at upcoming Annual General Meeting • Remco Steenbergen appointed as Sandoz CFO and member of Executive Committee as of July 1, 2024, and consequently not standing for re-election to Board of ...",
            "banner_image": "https://ml-eu.globenewswire.com/media/OWJmMGQ2NmMtODAyOS00NWQ3LTgzN2UtNDIxZDUxMWJmMGViLTEwMTQyODI=/tiny/Sandoz-International-GmbH.png",
            "source": "Business Insider",
            "category_within_source": "RSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.181593,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AOMFF",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "0.002006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TXG",
                    "relevance_score": "0.03399",
                    "ticker_sentiment_score": "0.004778",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.03399",
                    "ticker_sentiment_score": "0.004778",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Sandoz announces nominations to the Board of Directors and leadership change - Sandoz Group  ( OTC:SDZNY ) ",
            "url": "https://www.benzinga.com/pressreleases/24/03/g37474269/sandoz-announces-nominations-to-the-board-of-directors-and-leadership-change",
            "time_published": "20240305T060000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Mathai Mammen and Michael Rechsteiner nominated to stand for election to Sandoz Board of Directors at upcoming Annual General Meeting",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.174608,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AOMFF",
                    "relevance_score": "0.06623",
                    "ticker_sentiment_score": "0.002004",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TXG",
                    "relevance_score": "0.033144",
                    "ticker_sentiment_score": "0.00571",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.033144",
                    "ticker_sentiment_score": "0.00571",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson  ( JNJ )  Dips More Than Broader Market: What You Should Know",
            "url": "https://www.zacks.com/stock/news/2235639/johnson-johnson-jnj-dips-more-than-broader-market-what-you-should-know",
            "time_published": "20240304T224520",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Johnson & Johnson (JNJ) closed the most recent trading day at $159.84, moving -1.41% from the previous trading session.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default64.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.986564"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.135784,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.537213",
                    "ticker_sentiment_score": "0.128491",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "J&J  ( JNJ )  Secures Full FDA Nod for Rybrevant in Lung Cancer",
            "url": "https://www.zacks.com/stock/news/2235489/jj-jnj-secures-full-fda-nod-for-rybrevant-in-lung-cancer",
            "time_published": "20240304T165100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The approval is based on data from a late-stage study wherein treatment with J&J's (JNJ) Rybrevant plus chemotherapy reduced the disease-progression risk or death by 61% in certain NSCLC patients.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.997335"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.18996,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ADMA",
                    "relevance_score": "0.382925",
                    "ticker_sentiment_score": "0.200211",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ACET",
                    "relevance_score": "0.224903",
                    "ticker_sentiment_score": "0.052672",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.224903",
                    "ticker_sentiment_score": "-0.025716",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PBYI",
                    "relevance_score": "0.224903",
                    "ticker_sentiment_score": "0.111128",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Global Urinary Incontinence Treatment Devices Market Size is Estimated to Reach USD 6.02 billion by 2030, Growing at a CAGR of 6.58%: Straits Research",
            "url": "https://www.benzinga.com/pressreleases/24/03/g37453577/global-urinary-incontinence-treatment-devices-market-size-is-estimated-to-reach-usd-6-02-billion-b",
            "time_published": "20240304T130500",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "New York, United States, March 04, 2024 ( GLOBE NEWSWIRE ) -- A medical disease called urinary incontinence causes uncontrollable urine loss. Medical devices are used to treat chronic urine incontinence and to grow and strengthen the pelvic floor muscles.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.144111,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.03704",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.03704",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.03704",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.03704",
                    "ticker_sentiment_score": "0.105774",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BDX",
                    "relevance_score": "0.03704",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.03704",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors - Immunome  ( NASDAQ:IMNM ) , Shattuck Labs  ( NASDAQ:STTK ) ",
            "url": "https://www.benzinga.com/pressreleases/24/03/g37450970/shattuck-labs-announces-appointment-of-clay-siegall-ph-d-and-kate-sasser-ph-d-to-its-board-of-dire",
            "time_published": "20240304T120000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "AUSTIN, TX and DURHAM, NC, March 04, 2024 ( GLOBE NEWSWIRE ) -- Shattuck Labs, Inc. ( Shattuck ) STTK, a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.176944,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "IMNM",
                    "relevance_score": "0.09239",
                    "ticker_sentiment_score": "-0.026467",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GMAB",
                    "relevance_score": "0.046273",
                    "ticker_sentiment_score": "0.121464",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.046273",
                    "ticker_sentiment_score": "0.121464",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "STTK",
                    "relevance_score": "0.272282",
                    "ticker_sentiment_score": "-0.018778",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Dow companies made bigger-than-normal adjustments to profits in Q4",
            "url": "https://www.marketwatch.com/story/companies-in-the-dow-made-bigger-than-normal-adjustments-to-their-profits-in-q4-analysis-shows-08ba9fa9",
            "time_published": "20240303T150100",
            "authors": [
                "Bill Peters"
            ],
            "summary": "The median difference between per-share profit reported based on generally accepted accounting principles and the adjusted kind stood at 31%.",
            "banner_image": "https://images.mktw.net/im-72523698/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999996"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.119097,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JWN",
                    "relevance_score": "0.080323",
                    "ticker_sentiment_score": "0.11099",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TGT",
                    "relevance_score": "0.199037",
                    "ticker_sentiment_score": "0.036311",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIG",
                    "relevance_score": "0.080323",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VSCO",
                    "relevance_score": "0.080323",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.080323",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VZ",
                    "relevance_score": "0.080323",
                    "ticker_sentiment_score": "0.061468",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FL",
                    "relevance_score": "0.080323",
                    "ticker_sentiment_score": "0.11099",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.080323",
                    "ticker_sentiment_score": "0.061468",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KR",
                    "relevance_score": "0.159834",
                    "ticker_sentiment_score": "-0.024337",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NKE",
                    "relevance_score": "0.040212",
                    "ticker_sentiment_score": "0.106114",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AEO",
                    "relevance_score": "0.080323",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GPS",
                    "relevance_score": "0.080323",
                    "ticker_sentiment_score": "0.11099",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DOW",
                    "relevance_score": "0.080323",
                    "ticker_sentiment_score": "0.061468",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BURL",
                    "relevance_score": "0.080323",
                    "ticker_sentiment_score": "0.11099",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.080323",
                    "ticker_sentiment_score": "0.049765",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.080323",
                    "ticker_sentiment_score": "0.034513",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ROST",
                    "relevance_score": "0.080323",
                    "ticker_sentiment_score": "0.11099",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ANF",
                    "relevance_score": "0.080323",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DOCU",
                    "relevance_score": "0.080323",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRVL",
                    "relevance_score": "0.080323",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.040212",
                    "ticker_sentiment_score": "0.007873",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:UYU",
                    "relevance_score": "0.040212",
                    "ticker_sentiment_score": "0.05874",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Will Johnson & Johnson Be a Trillion-Dollar Stock by 2030?",
            "url": "https://www.fool.com/investing/2024/03/03/will-johnson-johnson-be-a-trillion-dollar-stock-by/",
            "time_published": "20240303T131400",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Can Johnson & Johnson stock become a hot buy for growth-focused investors, or is this mainly just a dividend play?",
            "banner_image": "https://g.foolcdn.com/editorial/images/766951/surprised-investors-looking-at-their-laptop.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.311497,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AMAM",
                    "relevance_score": "0.0699",
                    "ticker_sentiment_score": "-0.022483",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.619618",
                    "ticker_sentiment_score": "0.561967",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "3 Nuggets of Investing Wisdom From Warren Buffett's Latest Letter to Berkshire Hathaway Shareholders",
            "url": "https://www.fool.com/investing/2024/03/03/investing-wisdom-warren-buffett-berkshire-letter/",
            "time_published": "20240303T115500",
            "authors": [
                "James Brumley"
            ],
            "summary": "The Oracle of Omaha is still as good at explaining how he picks stocks as he is at actually picking them.",
            "banner_image": "https://g.foolcdn.com/editorial/images/766937/buffett16-tmf.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999897"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.04815,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "KO",
                    "relevance_score": "0.040348",
                    "ticker_sentiment_score": "0.022432",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.040348",
                    "ticker_sentiment_score": "0.08631",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.040348",
                    "ticker_sentiment_score": "-0.008791",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Berkshire Hathaway Has $168 Billion In Cash: These Stocks Should Be On Buffett's Buy List",
            "url": "https://www.forbes.com/sites/johndobosz/2024/03/02/berkshire-hathaway-has-168-billion-in-cash-these-stocks-should-be-on-buffetts-buy-list/",
            "time_published": "20240302T113000",
            "authors": [
                "John Dobosz"
            ],
            "summary": "Based on what Warren Buffett says and what he owns, it would not be surprising to see Berkshire buy stakes in these 13 stocks.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65e22f56538bd9faeb687c8b/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.714479"
                }
            ],
            "overall_sentiment_score": 0.31919,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AON",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.120496",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CINF",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.209412",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ULTA",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.175679",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.024634",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.05833",
                    "ticker_sentiment_score": "0.095983",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.087397",
                    "ticker_sentiment_score": "0.078257",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.1708",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KHC",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.024634",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.1708",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.145623",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OXY",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.024634",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MA",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.145623",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.1708",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AXP",
                    "relevance_score": "0.05833",
                    "ticker_sentiment_score": "0.095983",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HD",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.1708",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SIGI",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.209412",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WGO",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.117621",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IAUGF",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.120496",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ODFL",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.044952",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRSN",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.145623",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Mezzion Pharmaceuticals Announces Dr. Rahul Rathod of Boston Children's Hospital and Harvard Medical School as ... - PR Newswire",
            "url": "https://www.prnewswire.com/apac/news-releases/mezzion-pharmaceuticals-announces-dr-rahul-rathod-of-boston-childrens-hospital-and-harvard-medical-school-as-the-global-principal-investigator-for-the-confirmatory-pivotal-phase-3-trial-fuel-2-302077704.html",
            "time_published": "20240302T023241",
            "authors": [],
            "summary": "Mezzion Pharmaceuticals Announces Dr. Rahul Rathod of Boston Children's Hospital and Harvard Medical School as ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.210931,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.046363",
                    "ticker_sentiment_score": "0.050118",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "RYBREVANT®  ( amivantamab-vmjw )  in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations",
            "url": "https://www.prnewswire.com/news-releases/rybrevant-amivantamab-vmjw-in-combination-with-chemotherapy-is-the-first-fda-approved-therapy-for-first-line-treatment-of-patients-with-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations-302077581.html",
            "time_published": "20240301T205900",
            "authors": [
                "Johnson & Johnson"
            ],
            "summary": "RYBREVANT® ( amivantamab-vmjw ) in Combination With Chemotherapy Is the First FDA Approved Therapy for First ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/2303741/JJ_SingleLine_Red_RGB_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": -0.019362,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.174407",
                    "ticker_sentiment_score": "0.108791",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "JAMP Pharma Group announces the commercial launch and product availability for PrJamteki™, the first biosimilar of Stelara®  ( ustekinumab )  in Canada",
            "url": "https://www.newswire.ca/news-releases/jamp-pharma-group-announces-the-commercial-launch-and-product-availability-for-prjamteki-tm-the-first-biosimilar-of-stelara-r-ustekinumab-in-canada-892829386.html",
            "time_published": "20240301T192600",
            "authors": [
                "JAMP Pharma"
            ],
            "summary": "JAMP Pharma Group announces the commercial launch and product availability for PrJamteki™, the first biosimilar of ... Canada ...",
            "banner_image": "https://mma.prnewswire.com/media/2352688/JAMP_Pharma_JAMP_Pharma_Group_announces_the_commercial_launch_an.jpg?p=facebook",
            "source": "Canada Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.newswire.ca",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.322297,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ALVO",
                    "relevance_score": "0.075161",
                    "ticker_sentiment_score": "0.06154",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.075161",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.075161",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Judge rejects AstraZeneca's challenge to Medicare drug price negotiations",
            "url": "https://www.cnbc.com/2024/03/01/medicare-drug-price-negotiations-judge-rejects-astrazeneca-challenge.html",
            "time_published": "20240301T190250",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "U.S. District Judge Colm Connolly's decision comes one day before manufacturers have to respond to Medicare's initial price offers for their drugs.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107130655-1665090556176-gettyimages-1431082899-_m021740_4b5641b7-17d1-48f7-8db3-6aef2e513b99.jpeg?v=1709317769&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.026892,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.306963",
                    "ticker_sentiment_score": "0.250416",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.078611",
                    "ticker_sentiment_score": "-0.079089",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.078611",
                    "ticker_sentiment_score": "-0.079089",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.078611",
                    "ticker_sentiment_score": "-0.079089",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "This Firm Supplies Clean Power to AI Tech Companies. The CEO Wants More Credit.",
            "url": "https://www.barrons.com/amp/articles/aes-utility-energy-tech-ai-data-centers-feba4636",
            "time_published": "20240301T142700",
            "authors": [
                "Avi Salzman"
            ],
            "summary": "AES Has an AI Edge. The CEO Wants More Credit. ...",
            "banner_image": "https://images.barrons.com/im-27840959/social",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.904684"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.177295,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.164656",
                    "ticker_sentiment_score": "0.169015",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.055236",
                    "ticker_sentiment_score": "0.077846",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.055236",
                    "ticker_sentiment_score": "0.144049",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.055236",
                    "ticker_sentiment_score": "0.144049",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is WisdomTree U.S. Quality Dividend Growth ETF  ( DGRW )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2234343/is-wisdomtree-us-quality-dividend-growth-etf-dgrw-a-strong-etf-right-now",
            "time_published": "20240301T112006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default350.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999981"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.321684,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.111747",
                    "ticker_sentiment_score": "0.059292",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.111747",
                    "ticker_sentiment_score": "0.059292",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MORN",
                    "relevance_score": "0.056011",
                    "ticker_sentiment_score": "0.186024",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WT",
                    "relevance_score": "0.274628",
                    "ticker_sentiment_score": "0.37035",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.111747",
                    "ticker_sentiment_score": "0.059292",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Biocon shares gain on licence deal with Janssen, J&J for US markets",
            "url": "https://www.moneycontrol.com/news/business/stocks/biocon-shares-gain-on-licence-deal-with-janssen-jj-for-us-markets-12379491.html",
            "time_published": "20240301T041244",
            "authors": [],
            "summary": "Biocon Share Price | In an another development, the company's subsidiary received observations from US Food and Drug Administration ( USFDA ) .",
            "banner_image": "https://images.moneycontrol.com/static-mcnews/2024/03/WhatsApp-Image-2023-06-05-at-5.44.33-PM.jpeg?impolicy=website&width=168&height=118",
            "source": "Money Control",
            "category_within_source": "Buzzing Stocks",
            "source_domain": "www.moneycontrol.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.197051,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.149656",
                    "ticker_sentiment_score": "0.135655",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stocks to watch today, March 01: Paytm, Tata Group, Airtel, Biocon, Suven, Vedanta, L&T | | News on Markets",
            "url": "https://www.business-standard.com/markets/news/stocks-to-watch-paytm-tata-group-airtel-biocon-suven-vedanta-l-t-124030100083_1.html",
            "time_published": "20240301T020847",
            "authors": [
                "Harshita Singh"
            ],
            "summary": "Stocks to watch: Paytm, Tata Group, Airtel, Biocon, Suven, Vedanta, L&T Business Standard ...",
            "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-01/16/full/1705389250-0843.jpg?im=FeatureCrop,size=(826,465)",
            "source": "Business Standard",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.business-standard.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.218348,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "WMG",
                    "relevance_score": "0.147366",
                    "ticker_sentiment_score": "0.02422",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RNECF",
                    "relevance_score": "0.147366",
                    "ticker_sentiment_score": "0.012852",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FHYDF",
                    "relevance_score": "0.074001",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.074001",
                    "ticker_sentiment_score": "0.121075",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "We're trimming an embattled portfolio stock facing a binary event that could go either way",
            "url": "https://www.cnbc.com/2024/02/29/were-trimming-an-embattled-portfolio-stock-facing-a-binary-event-that-could-go-either-way.html",
            "time_published": "20240229T171455",
            "authors": [
                "Jim Cramer",
                "Jeff Marks"
            ],
            "summary": "The sale involves roughly one-quarter of our position to manage our downside risk ahead of a key court ruling.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107200471-1677528554272-NUP_200782_00284.jpg?v=1695136854&w=600&h=300&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.972756"
                }
            ],
            "overall_sentiment_score": 0.123069,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BHC",
                    "relevance_score": "0.509035",
                    "ticker_sentiment_score": "0.165216",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BLCO",
                    "relevance_score": "0.240489",
                    "ticker_sentiment_score": "0.096236",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.061003",
                    "ticker_sentiment_score": "0.051257",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pfizer  ( PFE )  Down 0.2% Since Last Earnings Report: Can It Rebound?",
            "url": "https://www.zacks.com/stock/news/2234048/pfizer-pfe-down-02-since-last-earnings-report-can-it-rebound",
            "time_published": "20240229T163036",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default39.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": -0.009646,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "PFE",
                    "relevance_score": "0.326035",
                    "ticker_sentiment_score": "0.132043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BNTX",
                    "relevance_score": "0.025817",
                    "ticker_sentiment_score": "-0.09522",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.102998",
                    "ticker_sentiment_score": "0.038442",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Urinary Tract Cancer Market To Grow At A CAGR Of More Than 19% With The Rising Prevalence Of Urinary Tract Infections As Per The Business Research Company's Urinary Tract Cancer Global Market Report 2024",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37398973/urinary-tract-cancer-market-to-grow-at-a-cagr-of-more-than-19-with-the-rising-prevalence-of-urinar",
            "time_published": "20240229T163000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "LONDON, Feb. 29, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's urinary tract cancer global market report 2024, the urinary tract cancer market has experienced remarkable growth in recent years, surging from $2.65 billion in 2023 to $3.21 billion in 2024, representing a ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.030025,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "PFE",
                    "relevance_score": "0.054983",
                    "ticker_sentiment_score": "-0.018085",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.054983",
                    "ticker_sentiment_score": "-0.018085",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Global Onychomycosis Treatment Market Size is Estimated to Reach USD 4.51 Billion by 2030, Growing at a CAGR of 5.61%: Straits Research",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37397003/global-onychomycosis-treatment-market-size-is-estimated-to-reach-usd-4-51-billion-by-2030-growing-",
            "time_published": "20240229T153500",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "New York, United States, Feb. 29, 2024 ( GLOBE NEWSWIRE ) -- Onychomycosis is a fungal condition that affects the fingernails and toenails and can be painful, ugly, and persistent. Several types of onychomycosis include proximal subungual, white superficial, and distal subungual.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.043083,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.038345",
                    "ticker_sentiment_score": "-0.056789",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.038345",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAYZF",
                    "relevance_score": "0.038345",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.038345",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.038345",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BHC",
                    "relevance_score": "0.038345",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.038345",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Biocon Biologics signs agreement with Janssen Biotech for psoriasis drug | Company News",
            "url": "https://www.business-standard.com/companies/news/biocon-biologics-signs-agreement-with-janssen-biotech-for-psoriasis-drug-124022901115_1.html",
            "time_published": "20240229T145228",
            "authors": [
                "Aneeka Chatterjee"
            ],
            "summary": "Biocon Biologics signs agreement with Janssen Biotech for psoriasis drug Business Standard ...",
            "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2021-09/17/full/1631878498-1779.jpeg?im=FitAndFill=(826,465)",
            "source": "Business Standard",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.business-standard.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.378675,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.13459",
                    "ticker_sentiment_score": "0.126703",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pfizer RSV vaccine maintains protection in older adults over two seasons in trial",
            "url": "https://www.cnbc.com/2024/02/29/pfizer-rsv-vaccine-protects-older-adults-over-two-seasons.html",
            "time_published": "20240229T130001",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "The results come ahead of a meeting of an advisory panel to the CDC, which will consider whether seniors should take RSV shots annually or every other year.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107243426-1684423445438-gettyimages-1265740892-dsc_6883.jpeg?v=1709188517&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": -0.024393,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.125789",
                    "ticker_sentiment_score": "0.218217",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.187705",
                    "ticker_sentiment_score": "0.216558",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.125789",
                    "ticker_sentiment_score": "0.027768",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.063091",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.063091",
                    "ticker_sentiment_score": "0.268528",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Want $1,000 in Ultra-Safe Annual Dividend Income? Invest $19,000 Into the Following 3 Time-Tested Dividend Kings.",
            "url": "https://www.fool.com/investing/2024/02/29/want-1000-safe-annual-dividend-income-invest-19000/",
            "time_published": "20240229T100600",
            "authors": [
                "Sean Williams"
            ],
            "summary": "These rock-solid dividend stocks, which sport an average yield of 5.26%, have raised their base annual payouts for between 54 and 62 consecutive years.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F766963%2Fperson-holding-cash-bills-money-hundred-dollar-fifty-dividend-income-invest-retire-spend-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.986714"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": 0.21729,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.027667",
                    "ticker_sentiment_score": "0.076141",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MO",
                    "relevance_score": "0.218571",
                    "ticker_sentiment_score": "0.113943",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TWOH",
                    "relevance_score": "0.027667",
                    "ticker_sentiment_score": "0.216319",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.245065",
                    "ticker_sentiment_score": "0.224374",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.027667",
                    "ticker_sentiment_score": "-0.046782",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.110335",
                    "ticker_sentiment_score": "0.003395",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "DRI Healthcare Trust Reports Fourth Quarter and Fiscal 2023 Results",
            "url": "https://www.newswire.ca/news-releases/dri-healthcare-trust-reports-fourth-quarter-and-fiscal-2023-results-808176485.html",
            "time_published": "20240228T220000",
            "authors": [
                "DRI Healthcare Trust"
            ],
            "summary": "- 82% royalty income growth over prior year period underscores transformative year - - Announcing 2024 royalty income guidance of US$153 to US$155 million, excluding milestone income and any new transactions - - Increasing quarterly cash distribution -",
            "banner_image": "https://mma.prnewswire.com/media/2350358/DRI_Healthcare_Trust_DRI_Healthcare_Trust_Reports_Fourth_Quarter.jpg?p=facebook",
            "source": "Canada Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.newswire.ca",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999894"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.312005,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MGNX",
                    "relevance_score": "0.008908",
                    "ticker_sentiment_score": "0.164782",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DHTRF",
                    "relevance_score": "0.017815",
                    "ticker_sentiment_score": "0.032198",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.008908",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSBHF",
                    "relevance_score": "0.008908",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ESALF",
                    "relevance_score": "0.008908",
                    "ticker_sentiment_score": "0.208694",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "OMER",
                    "relevance_score": "0.017815",
                    "ticker_sentiment_score": "0.168206",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.008908",
                    "ticker_sentiment_score": "0.164782",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Alexander Kalchev and Paul Ducré appointed CEOs of DDB Paris - Omnicom Group  ( NYSE:OMC ) ",
            "url": "https://www.benzinga.com/pressreleases/24/02/n37366456/alexander-kalchev-and-paul-ducr-appointed-ceos-of-ddb-paris",
            "time_published": "20240228T151800",
            "authors": [
                "PRNewswire"
            ],
            "summary": "A story of friendship and a natural transition PARIS, Feb. 28, 2024 /PRNewswire/ -- DDB Paris announces the elevation of globally acclaimed CCO Alexander Kalchev and Paul Ducré as new CEOs, together assuming the role of current CEO Jean-Luc Bravi who will become Chairman, DDB France.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.445592,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NKE",
                    "relevance_score": "0.043342",
                    "ticker_sentiment_score": "0.147493",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDNDF",
                    "relevance_score": "0.086556",
                    "ticker_sentiment_score": "0.125648",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OMC",
                    "relevance_score": "0.086556",
                    "ticker_sentiment_score": "0.128753",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REYN",
                    "relevance_score": "0.043342",
                    "ticker_sentiment_score": "0.122669",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.043342",
                    "ticker_sentiment_score": "0.147493",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UL",
                    "relevance_score": "0.086556",
                    "ticker_sentiment_score": "0.154656",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results",
            "url": "https://www.globenewswire.com/news-release/2024/02/28/2836795/0/en/Mersana-Therapeutics-Provides-Business-Update-and-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html",
            "time_published": "20240228T120000",
            "authors": [
                "Inc.",
                "Mersana Therapeutics"
            ],
            "summary": "CAMBRIDGE, Mass., Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Mersana Therapeutics, Inc. ( NASDAQ: MRSN ) , a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ( ADCs ) targeting cancers in areas of high unmet medical need, today ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/75b0bceb-3927-4f94-9ec8-22925b2a27a4",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.891286"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.576289"
                }
            ],
            "overall_sentiment_score": 0.139733,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MRSN",
                    "relevance_score": "0.093928",
                    "ticker_sentiment_score": "0.110136",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.023533",
                    "ticker_sentiment_score": "0.0661",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.163592",
                    "ticker_sentiment_score": "0.077457",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson Stock Has 33% Upside, According to 1 Wall Street Analyst",
            "url": "https://www.fool.com/investing/2024/02/28/johnson-johnson-stock-33-upside-street-analyst/",
            "time_published": "20240228T104900",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Management's thesis regarding the spinoff is now being tested.",
            "banner_image": "https://g.foolcdn.com/editorial/images/767030/three-investors-meet-with-paperwork.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.187113,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.122894",
                    "ticker_sentiment_score": "0.050146",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.463792",
                    "ticker_sentiment_score": "0.224755",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Nearing Retirement? These Stocks Are as Cautious as They Come",
            "url": "https://www.fool.com/investing/2024/02/28/nearing-retirement-these-stocks-are-as-cautious-as/",
            "time_published": "20240228T104400",
            "authors": [
                "Justin Pope"
            ],
            "summary": "Healthcare blue chips can provide retirees the consistency they need while growing their nest eggs further.",
            "banner_image": "https://media.ycharts.com/charts/36fce26a2d1d75f1c1bc8adfac20211b.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972476"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.307533,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.056943",
                    "ticker_sentiment_score": "0.038002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.056943",
                    "ticker_sentiment_score": "0.222",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.224903",
                    "ticker_sentiment_score": "0.159604",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.382925",
                    "ticker_sentiment_score": "0.361236",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "FOREX:GBP",
                    "relevance_score": "0.056943",
                    "ticker_sentiment_score": "0.098111",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Intracranial Stents Market Projected to Achieve USD 3.4 billion by 2031, with a 5.2% CAGR Growth: Transparency Market Research, Inc.",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37357287/intracranial-stents-market-projected-to-achieve-usd-3-4-billion-by-2031-with-a-5-2-cagr-growth-tra",
            "time_published": "20240228T100234",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Wilmington, Delaware, United States, Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global intracranial stents market is projected to grow at a CAGR of 5.2% from 2023 to 2031. As per the report published by TMR, a valuation of US$ 3.4 billion is anticipated for the ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.2082,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PEN",
                    "relevance_score": "0.040078",
                    "ticker_sentiment_score": "0.160178",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.040078",
                    "ticker_sentiment_score": "0.051125",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.040078",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMGTF",
                    "relevance_score": "0.11983",
                    "ticker_sentiment_score": "0.036437",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.040078",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.040078",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson  ( JNJ )  Rises But Trails Market: What Investors Should Know",
            "url": "https://www.zacks.com/stock/news/2232721/johnson-johnson-jnj-rises-but-trails-market-what-investors-should-know",
            "time_published": "20240227T224517",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Johnson & Johnson (JNJ) concluded the recent trading session at $160.98, signifying a +0.12% move from its prior day's close.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default118.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938793"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.135816,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.588876",
                    "ticker_sentiment_score": "0.066195",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's Why Investors Should Retain STERIS  ( STE )  Stock for Now",
            "url": "https://www.zacks.com/stock/news/2232656/heres-why-investors-should-retain-steris-ste-stock-for-now",
            "time_published": "20240227T172100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Investors are optimistic about STERIS (STE) on continuous recovery of healthcare procedures and upbeat 2024 guidance.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999974"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.1622,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KMB",
                    "relevance_score": "0.049322",
                    "ticker_sentiment_score": "0.052753",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SYK",
                    "relevance_score": "0.24289",
                    "ticker_sentiment_score": "0.06054",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "STE",
                    "relevance_score": "0.542075",
                    "ticker_sentiment_score": "0.118015",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.049322",
                    "ticker_sentiment_score": "0.052753",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BDX",
                    "relevance_score": "0.049322",
                    "ticker_sentiment_score": "0.131821",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COR",
                    "relevance_score": "0.195419",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.049322",
                    "ticker_sentiment_score": "0.052753",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAH",
                    "relevance_score": "0.195419",
                    "ticker_sentiment_score": "0.14429",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ECL",
                    "relevance_score": "0.049322",
                    "ticker_sentiment_score": "0.052753",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Josh Bersin Company Announces New Offerings to Accelerate HR's Transition to AI",
            "url": "https://www.prnewswire.com/news-releases/the-josh-bersin-company-announces-new-offerings-to-accelerate-hrs-transition-to-ai-302072619.html",
            "time_published": "20240227T140000",
            "authors": [
                "The Josh Bersin Company"
            ],
            "summary": "• New Josh Bersin Academy Certificate Program and in-depth playbooks and case studies • New AI offering Galileo™ available for HR problem solving and education • New AI experts to keynote Josh Bersin Company \"Irresistible\" future of work conference",
            "banner_image": "https://mma.prnewswire.com/media/1670975/The_Josh_Bersin_Company.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.339465,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.03792",
                    "ticker_sentiment_score": "0.241796",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PCRFF",
                    "relevance_score": "0.03792",
                    "ticker_sentiment_score": "0.241796",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CL",
                    "relevance_score": "0.03792",
                    "ticker_sentiment_score": "0.241796",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ACN",
                    "relevance_score": "0.03792",
                    "ticker_sentiment_score": "0.241796",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.03792",
                    "ticker_sentiment_score": "0.241796",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MAR",
                    "relevance_score": "0.03792",
                    "ticker_sentiment_score": "0.241796",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy",
            "url": "https://www.globenewswire.com/news-release/2024/02/27/2835913/0/en/GCANRx-Announces-Completion-of-Preclinical-Study-for-Neuropsychiatric-Cannabinoid-Therapy.html",
            "time_published": "20240227T124500",
            "authors": [
                "The Greater Cannabis Company",
                "Inc."
            ],
            "summary": "BALTIMORE, MD, Feb. 27, 2024 ( GLOBE NEWSWIRE ) -- Greater Cannabis Company, Inc. ( \"GCANRx\" or the \"Company\" ) ( OTC: GCAN ) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and consumer products today announced that it has completed the preclinical ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/de9f53cd-e801-432e-9bbe-884b7d855585",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": 0.196737,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GCAN",
                    "relevance_score": "0.17618",
                    "ticker_sentiment_score": "0.118118",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.044386",
                    "ticker_sentiment_score": "0.174742",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.044386",
                    "ticker_sentiment_score": "0.174742",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.044386",
                    "ticker_sentiment_score": "0.174742",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Should You Pick Johnson & Johnson Stock At $160?",
            "url": "https://www.forbes.com/sites/greatspeculations/2024/02/27/should-you-pick-johnson--johnson-stock-at-160/",
            "time_published": "20240227T120026",
            "authors": [
                "Trefis Team"
            ],
            "summary": "Johnson & Johnson ( NYSE: JNJ ) reported its Q4 results last month, with revenues and earnings marginally above the street estimates. The company reported revenue of $21.4 billion and adjusted earnings of $2.29 per share, compared to the consensus estimates of $21.0 billion and $2.28, ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/648bd40d9a7afc33dd5e44a9/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.996675"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.459462"
                }
            ],
            "overall_sentiment_score": 0.163924,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.057215",
                    "ticker_sentiment_score": "0.106006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.570165",
                    "ticker_sentiment_score": "0.230511",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Nested Therapeutics Strengthens Board of Directors with Appointment of New Chair and Directors",
            "url": "https://www.prnewswire.com/news-releases/nested-therapeutics-strengthens-board-of-directors-with-appointment-of-new-chair-and-directors-302071856.html",
            "time_published": "20240227T120000",
            "authors": [
                "Nested Therapeutics Inc."
            ],
            "summary": "CAMBRIDGE, Mass., Feb. 27, 2024 /PRNewswire/ -- Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, today announced the appointment of three members to its board of directors: John A.",
            "banner_image": "https://mma.prnewswire.com/media/2348138/Nested_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.135551,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ANAB",
                    "relevance_score": "0.050679",
                    "ticker_sentiment_score": "0.063497",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HESG",
                    "relevance_score": "0.050679",
                    "ticker_sentiment_score": "-0.01898",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABUS",
                    "relevance_score": "0.050679",
                    "ticker_sentiment_score": "0.023867",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TVTX",
                    "relevance_score": "0.050679",
                    "ticker_sentiment_score": "0.063497",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AFFY",
                    "relevance_score": "0.050679",
                    "ticker_sentiment_score": "0.063497",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCEL",
                    "relevance_score": "0.101154",
                    "ticker_sentiment_score": "0.041438",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.101154",
                    "ticker_sentiment_score": "0.04591",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KDNY",
                    "relevance_score": "0.101154",
                    "ticker_sentiment_score": "0.017067",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.101154",
                    "ticker_sentiment_score": "-0.020662",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRGX",
                    "relevance_score": "0.050679",
                    "ticker_sentiment_score": "0.063497",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2 Boston Partners Mutual Funds for Steady Returns",
            "url": "https://www.zacks.com/stock/news/2232161/2-boston-partners-mutual-funds-for-steady-returns",
            "time_published": "20240227T115500",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Invest in Boston Partners mutual funds like BPRRX and BPAVX for consistent returns.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/09/344.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.299022,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.080188",
                    "ticker_sentiment_score": "0.066037",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.080188",
                    "ticker_sentiment_score": "0.057893",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.080188",
                    "ticker_sentiment_score": "0.057893",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.080188",
                    "ticker_sentiment_score": "0.066037",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.080188",
                    "ticker_sentiment_score": "0.066037",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.080188",
                    "ticker_sentiment_score": "0.222574",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Pharmaceutical Industry Research Highlights Sustainability and Growth Opportunities Through 6P Framework Implementation",
            "url": "https://www.prnewswire.com/news-releases/pharmaceutical-industry-research-highlights-sustainability-and-growth-opportunities-through-6p-framework-implementation-302071441.html",
            "time_published": "20240227T011500",
            "authors": [
                "Research and Markets"
            ],
            "summary": "Pharmaceutical Industry Research Highlights Sustainability and Growth Opportunities Through 6P Framework ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.411257,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.062926",
                    "ticker_sentiment_score": "0.14035",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.062926",
                    "ticker_sentiment_score": "0.14035",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "These 4 Dividend ETFs Are a Retiree's Best Friend",
            "url": "https://www.fool.com/investing/2024/02/26/these-4-dividend-etfs-are-a-retirees-best-friend/",
            "time_published": "20240226T142400",
            "authors": [
                "Justin Pope"
            ],
            "summary": "Make retirement a breeze with stress-free ETFs.",
            "banner_image": "https://g.foolcdn.com/editorial/images/766555/happy-retirement.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999696"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.39187,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.274416",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.274416",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.274416",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.274416",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.087135",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.207524",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.207524",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.207524",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.274416",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Amazon joins 29 other 'blue chip' cos in Dow Jones Industrial Average | World News",
            "url": "https://www.business-standard.com/world-news/amazon-joins-29-other-blue-chip-cos-in-dow-jones-industrial-average-124022600828_1.html",
            "time_published": "20240226T133228",
            "authors": [
                "AP"
            ],
            "summary": "Amazon joins 29 other 'blue chip' cos in Dow Jones Industrial Average Business Standard ...",
            "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-02/16/full/1708048506-2242.jpg?im=FeatureCrop,size=(826,465)",
            "source": "Business Standard",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.business-standard.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999998"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.049337,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.043658",
                    "ticker_sentiment_score": "0.058522",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.043658",
                    "ticker_sentiment_score": "0.058522",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.043658",
                    "ticker_sentiment_score": "0.306782",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VZ",
                    "relevance_score": "0.043658",
                    "ticker_sentiment_score": "-0.05368",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HON",
                    "relevance_score": "0.043658",
                    "ticker_sentiment_score": "0.038981",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.043658",
                    "ticker_sentiment_score": "0.208461",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.173333",
                    "ticker_sentiment_score": "-0.032486",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.043658",
                    "ticker_sentiment_score": "0.208461",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.043658",
                    "ticker_sentiment_score": "0.038981",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.130453",
                    "ticker_sentiment_score": "-0.013135",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.173333",
                    "ticker_sentiment_score": "0.052535",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.043658",
                    "ticker_sentiment_score": "0.058522",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.043658",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.043658",
                    "ticker_sentiment_score": "0.038981",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXP",
                    "relevance_score": "0.043658",
                    "ticker_sentiment_score": "0.208461",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.043658",
                    "ticker_sentiment_score": "0.306782",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.130453",
                    "ticker_sentiment_score": "-0.096349",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Global Nanomedicine Market Report 2023-2028: United States Emerges as a Key Player",
            "url": "https://www.prnewswire.com/news-releases/global-nanomedicine-market-report-2023-2028-united-states-emerges-as-a-key-player-302070908.html",
            "time_published": "20240226T114500",
            "authors": [
                "Research and Markets"
            ],
            "summary": "DUBLIN, Feb. 26, 2024 /PRNewswire/ -- The \"Nanomedicine Market - Forecasts from 2023 to 2028\" report has been added to ResearchAndMarkets.com's offering. The medical application of nanotechnology is the focus of the interdisciplinary field of nanomedicine.",
            "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.234378,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ABT",
                    "relevance_score": "0.088147",
                    "ticker_sentiment_score": "0.109752",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.044141",
                    "ticker_sentiment_score": "0.104084",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.044141",
                    "ticker_sentiment_score": "0.104084",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.044141",
                    "ticker_sentiment_score": "0.104084",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Amazon joins 29 other 'blue chip' companies in the Dow Jones Industrial Average",
            "url": "https://apnews.com/article/amazon-walgreens-dow-jones-industrial-average-stock-market-7e7d5e71ee10f7612a45ac1c8bb82c4e",
            "time_published": "20240226T080150",
            "authors": [
                "ALEX VEIGA"
            ],
            "summary": "Amazon.com Inc. is joining the ranks of one of Wall Street's oldest and most exclusive stock indexes: The Dow Jones Industrial Average. The e-commerce pioneer will officially take its position among the 30-company Dow before the open of trading Monday, replacing drugstore operator Walgreens Boots ...",
            "banner_image": "https://dims.apnews.com/dims4/default/8f3f46b/2147483647/strip/true/crop/2070x1379+66+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fe4%2Fd8%2F3d845bb2445e48452a60b7cf9ff9%2Fd5f048f2446645b3b2987c97b1c501f3",
            "source": "Associated Press",
            "category_within_source": "Markets",
            "source_domain": "apnews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999998"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.051717,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.045918",
                    "ticker_sentiment_score": "0.058718",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.045918",
                    "ticker_sentiment_score": "0.058718",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.045918",
                    "ticker_sentiment_score": "0.307569",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VZ",
                    "relevance_score": "0.045918",
                    "ticker_sentiment_score": "-0.058941",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HON",
                    "relevance_score": "0.045918",
                    "ticker_sentiment_score": "0.039229",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.045918",
                    "ticker_sentiment_score": "0.209235",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.182162",
                    "ticker_sentiment_score": "-0.036666",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.045918",
                    "ticker_sentiment_score": "0.209235",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.045918",
                    "ticker_sentiment_score": "0.039229",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.137148",
                    "ticker_sentiment_score": "-0.014725",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.182162",
                    "ticker_sentiment_score": "0.055967",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.045918",
                    "ticker_sentiment_score": "0.058718",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.045918",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.045918",
                    "ticker_sentiment_score": "0.039229",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXP",
                    "relevance_score": "0.045918",
                    "ticker_sentiment_score": "0.209235",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.045918",
                    "ticker_sentiment_score": "0.307569",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.137148",
                    "ticker_sentiment_score": "-0.098838",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "NOT REAL NEWS: A look at what didn't happen this week",
            "url": "https://apnews.com/article/fact-check-misinformation-c99b70fbd4b0ac0f957305501fb89783",
            "time_published": "20240223T215100",
            "authors": [
                "MELISSA GOLDIN"
            ],
            "summary": "A roundup of some of the most popular but completely untrue stories and visuals of the week. None of these are legit, even though they were shared widely on social media. The Associated Press checked them out. Executive Order 9066 authorized Japanese detention during World War II, not gift cards ...",
            "banner_image": "https://dims.apnews.com/dims4/default/baed137/2147483647/strip/true/crop/3549x2364+26+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F4f%2Fc3%2Faababc88cfd92417920ff4d2c1e0%2F29355eddf7a44d6f99ee07e1b7b64905",
            "source": "Associated Press",
            "category_within_source": "Markets",
            "source_domain": "apnews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.036505,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVAX",
                    "relevance_score": "0.024775",
                    "ticker_sentiment_score": "0.065689",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.024775",
                    "ticker_sentiment_score": "0.065689",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.024775",
                    "ticker_sentiment_score": "0.065689",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.024775",
                    "ticker_sentiment_score": "0.065689",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.024775",
                    "ticker_sentiment_score": "0.065689",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Red Cross did not ban people with COVID-19 vaccinations from donating blood",
            "url": "https://apnews.com/article/fact-check-red-cross-donate-blood-covid-vaccine-372009322832",
            "time_published": "20240223T212900",
            "authors": [
                "MELISSA GOLDIN"
            ],
            "summary": "CLAIM: The American Red Cross banned people who have received a COVID-19 vaccine from donating blood because it is \"tainted.\" AP'S ASSESSMENT: False. No potential donors are deemed ineligible solely due to COVID-19 vaccines, a Red Cross spokesperson told The Associated Press.",
            "banner_image": "https://dims.apnews.com/dims4/default/95127ce/2147483647/strip/true/crop/4033x2686+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F00%2F0c%2F826dd6e1596af4b2be8aec655449%2F7e930b176591435993293e01aa8402b3",
            "source": "Associated Press",
            "category_within_source": "Markets",
            "source_domain": "apnews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.074857,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVAX",
                    "relevance_score": "0.061159",
                    "ticker_sentiment_score": "0.073002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.061159",
                    "ticker_sentiment_score": "0.073002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.061159",
                    "ticker_sentiment_score": "0.073002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.061159",
                    "ticker_sentiment_score": "0.073002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.061159",
                    "ticker_sentiment_score": "0.073002",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Extremity Products Market size to grow by USD 1.61 billion from 2022-2027, Acumed LLC, Artificial Limbs ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/extremity-products-market-size-to-grow-by-usd-1-61-billion-from-2022-2027--acumed-llc-artificial-limbs-manufacturing-corp-of-india-aspire-medical-innovation-to-emerge-as-some-of-the-key-companies-technavio-302068993.html",
            "time_published": "20240223T164800",
            "authors": [],
            "summary": "Extremity Products Market size to grow by USD 1.61 billion from 2022-2027, Acumed LLC, Artificial Limbs ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.322161,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ZBH",
                    "relevance_score": "0.038468",
                    "ticker_sentiment_score": "0.056626",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNN",
                    "relevance_score": "0.038468",
                    "ticker_sentiment_score": "0.056626",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SYK",
                    "relevance_score": "0.038468",
                    "ticker_sentiment_score": "0.056626",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.038468",
                    "ticker_sentiment_score": "0.056626",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.038468",
                    "ticker_sentiment_score": "0.056626",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OMI",
                    "relevance_score": "0.038468",
                    "ticker_sentiment_score": "0.056626",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CNMD",
                    "relevance_score": "0.038468",
                    "ticker_sentiment_score": "0.056626",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Evaluating Johnson & Johnson Against Peers In Pharmaceuticals Industry - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/insights/news/24/02/37287246/evaluating-johnson-amp-johnson-against-peers-in-pharmaceuticals-industry",
            "time_published": "20240223T160055",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "In today's fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating Johnson & Johnson JNJ in relation to its major competitors ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.961735"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.214057,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.063594",
                    "ticker_sentiment_score": "0.139129",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.423504",
                    "ticker_sentiment_score": "0.354442",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "2 Top Dividend Stocks To Watch Today",
            "url": "https://stockmarket.com/featured/2-top-dividend-stocks-to-watch-today-2024-02-23",
            "time_published": "20240223T145338",
            "authors": [
                "Josh Dylan"
            ],
            "summary": "Dividends are payments made by a corporation to its shareholders, usually derived from the company's profits. Dividend stocks are those issued by companies that regularly distribute a portion of their earnings to shareholders.",
            "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2020/08/johnson-and-johnson.jpg",
            "source": "StockMarket.com",
            "category_within_source": "n/a",
            "source_domain": "stockmarket.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999999"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.268748,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "UNH",
                    "relevance_score": "0.411176",
                    "ticker_sentiment_score": "0.253956",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.411176",
                    "ticker_sentiment_score": "0.272983",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Spinal implants Market to Expand at a 5.2% CAGR, to Attain a USD 16.7 billion Valuation by 2031 | Exclusive Report by Transparency Market Research Inc.",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37280677/spinal-implants-market-to-expand-at-a-5-2-cagr-to-attain-a-usd-16-7-billion-valuation-by-2031-excl",
            "time_published": "20240223T103006",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Wilmington, Delaware, United States, Feb. 23, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global spinal implant market was projected to attain US$ 10.6 billion in 2022. It is anticipated to garner a 5.2% CAGR from 2023 to 2031, and by 2031, the market is likely to attain ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.093955,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ATCN",
                    "relevance_score": "0.040212",
                    "ticker_sentiment_score": "0.091237",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.040212",
                    "ticker_sentiment_score": "0.05115",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMGTF",
                    "relevance_score": "0.12023",
                    "ticker_sentiment_score": "0.051158",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.040212",
                    "ticker_sentiment_score": "0.218994",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why Is Johnson & Johnson  ( JNJ )  Down 0.2% Since Last Earnings Report?",
            "url": "https://www.zacks.com/stock/news/2230334/why-is-johnson-johnson-jnj-down-02-since-last-earnings-report",
            "time_published": "20240222T163020",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default85.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999997"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                }
            ],
            "overall_sentiment_score": 0.237553,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.105026",
                    "ticker_sentiment_score": "0.053974",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Surgical Staplers Market Revenue to Reach USD 8.5 billion by 2031 | Says Transparency Market Research, Inc.",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37262345/surgical-staplers-market-revenue-to-reach-usd-8-5-billion-by-2031-says-transparency-market-researc",
            "time_published": "20240222T144000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Wilmington, Delaware, United States, Feb. 22, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global surgical staplers market is estimated to flourish at a CAGR of 6.9% from 2023 to 2031.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.363138,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LEIC",
                    "relevance_score": "0.033144",
                    "ticker_sentiment_score": "0.148844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.033144",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BDX",
                    "relevance_score": "0.033144",
                    "ticker_sentiment_score": "-0.211925",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.099202",
                    "ticker_sentiment_score": "0.044504",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.06623",
                    "ticker_sentiment_score": "0.099432",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CNMD",
                    "relevance_score": "0.099202",
                    "ticker_sentiment_score": "0.223381",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMGTF",
                    "relevance_score": "0.099202",
                    "ticker_sentiment_score": "0.1188",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Students graduating with a Rutgers MBA benefit from robust New Jersey job market - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/students-graduating-with-a-rutgers-mba-benefit-from-robust-new-jersey-job-market-302068310.html",
            "time_published": "20240222T133000",
            "authors": [],
            "summary": "Students graduating with a Rutgers MBA benefit from robust New Jersey job market PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.576289"
                }
            ],
            "overall_sentiment_score": 0.338966,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DELL",
                    "relevance_score": "0.043421",
                    "ticker_sentiment_score": "0.045803",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.043421",
                    "ticker_sentiment_score": "0.117846",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson  ( JNJ )  Rises Higher Than Market: Key Facts",
            "url": "https://www.zacks.com/stock/news/2229635/johnson-johnson-jnj-rises-higher-than-market-key-facts",
            "time_published": "20240221T224519",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "In the most recent trading session, Johnson & Johnson (JNJ) closed at $158.68, indicating a +0.52% shift from the previous trading day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default62.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938793"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.206997,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.548363",
                    "ticker_sentiment_score": "0.252117",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Global Ophthalmic Drugs Market Size is Estimated to Reach USD 62.55 billion by 2030, Growing at a CAGR of 7.4%: Straits Research",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37238229/global-ophthalmic-drugs-market-size-is-estimated-to-reach-usd-62-55-billion-by-2030-growing-at-a-c",
            "time_published": "20240221T152000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "New York, United States, Feb. 21, 2024 ( GLOBE NEWSWIRE ) -- Anti-infectives in a product designed specifically to be injected into or applied to the eye or eyes are known as ophthalmic anti-infectives. An example of an anti-infective for the eyes is eyedrops, gels, and ointments.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.211074,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.038655",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAYZF",
                    "relevance_score": "0.038655",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.038655",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALC",
                    "relevance_score": "0.115602",
                    "ticker_sentiment_score": "0.137469",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KALA",
                    "relevance_score": "0.038655",
                    "ticker_sentiment_score": "0.323546",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CHRS",
                    "relevance_score": "0.038655",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.038655",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.038655",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.077218",
                    "ticker_sentiment_score": "0.043676",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Immix Biopharma 12 Month Review Progress Update",
            "url": "https://www.globenewswire.com/news-release/2024/02/21/2832855/0/en/Immix-Biopharma-12-Month-Review-Progress-Update.html",
            "time_published": "20240221T143100",
            "authors": [
                "Immix Biopharma",
                "Inc."
            ],
            "summary": "LOS ANGELES, Feb. 21, 2024 ( GLOBE NEWSWIRE ) -- Immix Biopharma, Inc. ( Nasdaq: IMMX ) , a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter.",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/b46d5687-65de-44df-81d5-e36f2665d8e7",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.139016,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BAC",
                    "relevance_score": "0.040795",
                    "ticker_sentiment_score": "0.145594",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IMMX",
                    "relevance_score": "0.241085",
                    "ticker_sentiment_score": "0.133816",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.020404",
                    "ticker_sentiment_score": "-0.026128",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.020404",
                    "ticker_sentiment_score": "-0.026128",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Investors Heavily Search Johnson & Johnson  ( JNJ ) : Here is What You Need to Know",
            "url": "https://www.zacks.com/stock/news/2229159/investors-heavily-search-johnson-johnson-jnj-here-is-what-you-need-to-know",
            "time_published": "20240221T140023",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default265.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.54554"
                }
            ],
            "overall_sentiment_score": 0.224281,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.477606",
                    "ticker_sentiment_score": "0.142358",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Generative AI Contracting Copilots Drive Icertis Above $250 Million in Annual Recurring Revenue",
            "url": "https://www.prnewswire.com/news-releases/generative-ai-contracting-copilots-drive-icertis-above-250-million-in-annual-recurring-revenue-302066928.html",
            "time_published": "20240221T140000",
            "authors": [
                "Icertis"
            ],
            "summary": "BELLEVUE, Wash., Feb. 21, 2024 /PRNewswire/ -- Icertis, the global leader in AI-powered contract intelligence, today announced that the launch of Icertis Copilots and continued adoption of contract intelligence worldwide have driven the company above $250 million in annual recurring revenue ( ...",
            "banner_image": "https://mma.prnewswire.com/media/371539/Icertis_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.427902,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BBY",
                    "relevance_score": "0.059341",
                    "ticker_sentiment_score": "0.198024",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.118354",
                    "ticker_sentiment_score": "0.221493",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LW",
                    "relevance_score": "0.059341",
                    "ticker_sentiment_score": "0.198024",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MUR",
                    "relevance_score": "0.059341",
                    "ticker_sentiment_score": "0.198024",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "G",
                    "relevance_score": "0.176717",
                    "ticker_sentiment_score": "0.349068",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.059341",
                    "ticker_sentiment_score": "0.198024",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "2 Beaten-Down Stocks to Buy and Hold for 10 Years",
            "url": "https://www.fool.com/investing/2024/02/21/2-beaten-down-stocks-to-buy-and-hold-for-10-years/",
            "time_published": "20240221T133000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "One is a longtime healthcare leader, the other a newcomer. both have bright futures despite recent obstacles.",
            "banner_image": "https://media.ycharts.com/charts/cdbbf2d57e6e5084f13bf60b62c503c3.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938793"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.35644,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DOCS",
                    "relevance_score": "0.380736",
                    "ticker_sentiment_score": "0.420511",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.33628",
                    "ticker_sentiment_score": "0.331177",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Topical Antibiotics Market Size Projected to Reach USD 10.0 billion by 2031, With 5.1% CAGR: Transparency Market Research, Inc.",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37229711/topical-antibiotics-market-size-projected-to-reach-usd-10-0-billion-by-2031-with-5-1-cagr-transpar",
            "time_published": "20240221T054000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Wilmington, Delaware, United States, Feb. 21, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global topical antibiotics market is estimated to flourish at a CAGR of 5.1% from 2023 to 2031.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.385265,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.034831",
                    "ticker_sentiment_score": "0.050061",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAYZF",
                    "relevance_score": "0.034831",
                    "ticker_sentiment_score": "0.18334",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MAYNF",
                    "relevance_score": "0.034831",
                    "ticker_sentiment_score": "-0.131195",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.069596",
                    "ticker_sentiment_score": "0.196575",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BHC",
                    "relevance_score": "0.069596",
                    "ticker_sentiment_score": "0.119071",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TARO",
                    "relevance_score": "0.069596",
                    "ticker_sentiment_score": "0.280263",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMGTF",
                    "relevance_score": "0.104228",
                    "ticker_sentiment_score": "0.079915",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.069596",
                    "ticker_sentiment_score": "0.196575",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PRGO",
                    "relevance_score": "0.034831",
                    "ticker_sentiment_score": "0.195164",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "TECVAYLI®  ( teclistamab-cqyv )  biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma",
            "url": "https://www.prnewswire.com/news-releases/tecvayli-teclistamab-cqyv-biweekly-dosing-approved-by-the-us-fda-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma-302066627.html",
            "time_published": "20240220T212600",
            "authors": [
                "Johnson & Johnson"
            ],
            "summary": "TECVAYLI® ( teclistamab-cqyv ) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/2343818/Johnson_and_Johnson_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.009673,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.12142",
                    "ticker_sentiment_score": "0.097038",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/insights/options/24/02/37219687/johnson-johnson-options-trading-a-deep-dive-into-market-sentiment",
            "time_published": "20240220T184544",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Deep-pocketed investors have adopted a bearish approach towards Johnson & Johnson JNJ, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.145523,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.071145",
                    "ticker_sentiment_score": "0.139868",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.071145",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.673971",
                    "ticker_sentiment_score": "0.344785",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Congenital Diaphragmatic Hernia Drugs Market Size is Expected to Reach $5.8 Billion By 2028 At A CAGR Of More Than 7% As Per The Business Research Company's Congenital Diaphragmatic Hernia Drugs Global Market Report 2024",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37216844/congenital-diaphragmatic-hernia-drugs-market-size-is-expected-to-reach-5-8-billion-by-2028-at-a-ca",
            "time_published": "20240220T163000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "LONDON, Feb. 20, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Congenital Diaphragmatic Hernia Drugs Global Market Report 2024, the global congenital diaphragmatic hernia ( CDH ) drugs market has experienced robust expansion in recent years, driven by various factors ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.35108,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVS",
                    "relevance_score": "0.061631",
                    "ticker_sentiment_score": "0.00901",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.061631",
                    "ticker_sentiment_score": "0.00901",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.061631",
                    "ticker_sentiment_score": "0.00901",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.061631",
                    "ticker_sentiment_score": "0.00901",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Antiparasitic Drugs Industry Poised For Robust Growth: Market To Grow At A Rate Of More Than 6% As Per The Business Research Company's Antiparasitic Drugs Global Market Report 2024",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37216848/antiparasitic-drugs-industry-poised-for-robust-growth-market-to-grow-at-a-rate-of-more-than-6-as-p",
            "time_published": "20240220T163000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "LONDON, Feb. 20, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Antiparasitic Drugs Global Market Report 2024, the antiparasitic drugs market is experiencing robust expansion.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.208088,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PFE",
                    "relevance_score": "0.059785",
                    "ticker_sentiment_score": "0.124002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.059785",
                    "ticker_sentiment_score": "0.124002",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Complicated Skin And Skin Structure Infections Drugs Market Anticipates Significant Growth At Rate Of 9.7% Through 2024-2028 As Per TBRC's Complicated Skin And Skin Structure Infections Drugs Global Market Report 2024",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37216846/complicated-skin-and-skin-structure-infections-drugs-market-anticipates-significant-growth-at-rate",
            "time_published": "20240220T163000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "LONDON, Feb. 20, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Complicated Skin And Skin Structure Infections Drugs Global Market Report 2024, the complicated skin and skin structure infections drugs market has experienced rapid expansion, driven by a myriad of factors ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.036973,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVS",
                    "relevance_score": "0.056407",
                    "ticker_sentiment_score": "0.093866",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.056407",
                    "ticker_sentiment_score": "0.093866",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.056407",
                    "ticker_sentiment_score": "0.093866",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Top 20 global biopharmaceutical companies report 1.6% market capitalization growth to $3.67 trillion in 2023, reveals GlobalData",
            "url": "https://www.investorideas.com/news/2024/biotech/02201Global-Biopharmaceutical.asp",
            "time_published": "20240220T150551",
            "authors": [],
            "summary": "Top 20 global biopharmaceutical companies report 1.6% market capitalization growth to $3.67 trillion in 2023, reveals ... ...",
            "banner_image": null,
            "source": "Investor Ideas",
            "category_within_source": "n/a",
            "source_domain": "www.investorideas.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.152626,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.159922",
                    "ticker_sentiment_score": "0.108103",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.159922",
                    "ticker_sentiment_score": "-0.036799",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GLDAF",
                    "relevance_score": "0.159922",
                    "ticker_sentiment_score": "0.010941",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.053629",
                    "ticker_sentiment_score": "0.260895",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SKXJF",
                    "relevance_score": "0.053629",
                    "ticker_sentiment_score": "-0.175762",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "DSKYF",
                    "relevance_score": "0.053629",
                    "ticker_sentiment_score": "-0.175762",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.107016",
                    "ticker_sentiment_score": "-0.208134",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.053629",
                    "ticker_sentiment_score": "0.260895",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.107016",
                    "ticker_sentiment_score": "-0.208134",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.159922",
                    "ticker_sentiment_score": "-0.069573",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 American Century Mutual Funds for Excellent Returns",
            "url": "https://www.zacks.com/stock/news/2228248/3-american-century-mutual-funds-for-excellent-returns",
            "time_published": "20240220T110300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Consider investing in American Century mutual funds like AFYDX, AGYWX and ALVDX for consistent performance.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a8/346.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.270926,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.132004",
                    "ticker_sentiment_score": "0.058955",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.132004",
                    "ticker_sentiment_score": "0.058955",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.132004",
                    "ticker_sentiment_score": "0.058955",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.06623",
                    "ticker_sentiment_score": "0.051063",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.06623",
                    "ticker_sentiment_score": "0.051063",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.06623",
                    "ticker_sentiment_score": "0.051063",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Respiratory Disease Vaccine Market Overview 2024-2028: Market Size To Reach $76.1 Billion By 2028 As Per The Business Research Company's Respiratory Disease Vaccine Global Market Report 2024",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37202268/respiratory-disease-vaccine-market-overview-2024-2028-market-size-to-reach-76-1-billion-by-2028-as",
            "time_published": "20240219T163000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "LONDON, Feb. 19, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Respiratory Disease Vaccine Global Market Report 2024, the respiratory disease vaccine market is poised for robust expansion.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.303034,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PFE",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.226421",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.057767",
                    "ticker_sentiment_score": "0.197384",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "9.18% CAGR growth in Cancer Biologics Market by Product (Monoclonal antibodies, Cell and gene therapy, vaccines ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/9-18-cagr-growth-in-cancer-biologics-market-by-product-monoclonal-antibodies-cell-and-gene-therapy-vaccines-and-others-route-of-administration-and-geography--global-forecast-to-2028--302064076.html",
            "time_published": "20240219T154000",
            "authors": [],
            "summary": "9.18% CAGR growth in Cancer Biologics Market by Product ( Monoclonal antibodies, Cell and gene therapy, vaccines ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.04391,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.058472",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JAZZ",
                    "relevance_score": "0.058472",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAYZF",
                    "relevance_score": "0.058472",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.058472",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VTRS",
                    "relevance_score": "0.058472",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.058472",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.058472",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.058472",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.058472",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OPHLF",
                    "relevance_score": "0.058472",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Smartest Dividend Stocks to Buy With $400 Right Now",
            "url": "https://www.fool.com/investing/2024/02/19/the-smartest-dividend-stocks-to-buy-with-400-right/",
            "time_published": "20240219T103500",
            "authors": [
                "Justin Pope"
            ],
            "summary": "These companies will build an ever-growing stream of passive income, one share at a time.",
            "banner_image": "https://g.foolcdn.com/editorial/images/765205/group_of_nike_shoes_posed_nke.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999612"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": 0.310115,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NKE",
                    "relevance_score": "0.290033",
                    "ticker_sentiment_score": "0.305671",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PM",
                    "relevance_score": "0.243376",
                    "ticker_sentiment_score": "0.226793",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.147516",
                    "ticker_sentiment_score": "0.147446",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Oregon Rethinks Groundbreaking Drug Decriminalization Amid Escalating Opioid Crisis",
            "url": "https://www.benzinga.com/news/24/02/37197005/oregon-rethinks-groundbreaking-drug-decriminalization-amid-escalating-opioid-crisis",
            "time_published": "20240219T045232",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "In the wake of the escalating opioid crisis, the state of Oregon is reconsidering its groundbreaking drug decriminalization legislation. This move comes as the state grapples with a surge in drug-related fatalities and a lack of effective implementation of the existing law.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/66th-SFS-carries-opioid-overdose-medicat_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.080168,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.065866",
                    "ticker_sentiment_score": "-0.108181",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.065866",
                    "ticker_sentiment_score": "-0.108181",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "If You Invested $10,000 in Johnson & Johnson Stock in 2004, This Is How Much You Would Have Today",
            "url": "https://www.fool.com/investing/2024/02/18/if-you-invested-10000-in-johnson-johnson-stock-in/",
            "time_published": "20240218T135800",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Johnson & Johnson has been a stalwart in the healthcare industry for decades, but has it made for a good investment?",
            "banner_image": "https://g.foolcdn.com/editorial/images/765090/investor-calculating-stock-returns-on-a-calculator.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.246853,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.732373",
                    "ticker_sentiment_score": "0.424893",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "3 Unstoppable Dividend Stocks That Could Pay You for Life",
            "url": "https://www.fool.com/investing/2024/02/17/3-unstoppable-dividend-stocks-that-could-pay-you-f/",
            "time_published": "20240217T145100",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "There are no certainties in life or on the stock market. These companies' dividends are about as close as we can get.",
            "banner_image": "https://g.foolcdn.com/editorial/images/764583/physician-giving-medicine-to-elderly-patient.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.341848,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.278486",
                    "ticker_sentiment_score": "0.35424",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "MPW",
                    "relevance_score": "0.047371",
                    "ticker_sentiment_score": "0.13966",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "V",
                    "relevance_score": "0.365389",
                    "ticker_sentiment_score": "0.463746",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.278486",
                    "ticker_sentiment_score": "0.244959",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.047371",
                    "ticker_sentiment_score": "0.13966",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Tips To Negotiate Remote Work  ( At Your Current Job ) ",
            "url": "https://www.forbes.com/sites/shodewan/2024/02/16/3-tips-to-negotiate-remote-work-at-your-current-job/",
            "time_published": "20240216T202450",
            "authors": [
                "Sho Dewan"
            ],
            "summary": "Remote work has become increasingly popular. Initially, it was just a COVID-19 pandemic response, but through the years, it has shown promising outcomes. It offers flexibility in work hours and location, as well as cost-saving opportunities.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65cfc450dc59eb2fde4a265e/0x0.jpg?format=jpg&crop=4729,2659,x0,y0,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.504168,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.058047",
                    "ticker_sentiment_score": "0.242223",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SPLK",
                    "relevance_score": "0.058047",
                    "ticker_sentiment_score": "0.242223",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.058047",
                    "ticker_sentiment_score": "0.242223",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Inflation Devices Market Anticipated to Surpass USD 851.8 million by 2031, Projected a CAGR of 5.2% - Reports Transparency Market Research, Inc.",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37182636/inflation-devices-market-anticipated-to-surpass-usd-851-8-million-by-2031-projected-a-cagr-of-5-2-",
            "time_published": "20240216T164000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Wilmington, Delaware, United States, Feb. 16, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The inflation devices industry was worth US$ 537.7 million in 2022. The industry is projected to expand at a CAGR of 5.2% from 2023 to 2031, reaching more than US$ 851.8 million by 2031.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.10024,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.035821",
                    "ticker_sentiment_score": "0.050279",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MMSI",
                    "relevance_score": "0.035821",
                    "ticker_sentiment_score": "-0.094617",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMGTF",
                    "relevance_score": "0.107175",
                    "ticker_sentiment_score": "0.139815",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.035821",
                    "ticker_sentiment_score": "-0.094617",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.035821",
                    "ticker_sentiment_score": "0.039217",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.035821",
                    "ticker_sentiment_score": "-0.094617",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What the Options Market Tells Us About Johnson & Johnson - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/insights/options/24/02/37181577/what-the-options-market-tells-us-about-johnson-johnson",
            "time_published": "20240216T154610",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson JNJ we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.127747,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.074692",
                    "ticker_sentiment_score": "0.140431",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.074692",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.601191",
                    "ticker_sentiment_score": "0.267101",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months",
            "url": "https://www.fool.com/investing/2024/02/16/wall-street-thinks-these-3-stocks-are-hidden-gems/",
            "time_published": "20240216T105000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Analysts are quite bullish about these beaten-down stocks.",
            "banner_image": "https://g.foolcdn.com/editorial/images/765200/oil-rig-workers-talking.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.714479"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.234969,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BABA",
                    "relevance_score": "0.421485",
                    "ticker_sentiment_score": "0.231642",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SLB",
                    "relevance_score": "0.366061",
                    "ticker_sentiment_score": "0.140709",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.063258",
                    "ticker_sentiment_score": "0.042253",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RPRX",
                    "relevance_score": "0.366061",
                    "ticker_sentiment_score": "0.015773",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.063258",
                    "ticker_sentiment_score": "0.042253",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.063258",
                    "ticker_sentiment_score": "0.042253",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Global Advanced Drug Delivery Systems Market Report 2024: Review of Patents and Patent Applications Filed on Drug Delivery Release Mechanisms and Novel Applications",
            "url": "https://www.prnewswire.com/news-releases/global-advanced-drug-delivery-systems-market-report-2024-review-of-patents-and-patent-applications-filed-on-drug-delivery-release-mechanisms-and-novel-applications-302063265.html",
            "time_published": "20240215T224500",
            "authors": [
                "Research and Markets"
            ],
            "summary": "Global Advanced Drug Delivery Systems Market Report 2024: Review of Patents and Patent Applications Filed on Drug ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.163653,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVS",
                    "relevance_score": "0.042876",
                    "ticker_sentiment_score": "0.09682",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.042876",
                    "ticker_sentiment_score": "0.09682",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.042876",
                    "ticker_sentiment_score": "0.09682",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.042876",
                    "ticker_sentiment_score": "0.09682",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Coca-Cola Boosts Its Dividend Again",
            "url": "https://www.barrons.com/amp/articles/coca-cola-dividend-4ced4850",
            "time_published": "20240215T205000",
            "authors": [
                "Andrew Bary"
            ],
            "summary": "Coca-Cola Lifts Dividend by ...",
            "banner_image": "https://images.barrons.com/im-77493230/social",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.318442,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PEP",
                    "relevance_score": "0.31482",
                    "ticker_sentiment_score": "0.246831",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.582526",
                    "ticker_sentiment_score": "0.688049",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.31482",
                    "ticker_sentiment_score": "0.084392",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.31482",
                    "ticker_sentiment_score": "0.084392",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024",
            "url": "https://www.prnewswire.com/news-releases/alkermes-plc-reports-financial-results-for-the-fourth-quarter-and-year-ended-dec-31-2023-and-provides-financial-expectations-for-2024-302062983.html",
            "time_published": "20240215T120000",
            "authors": [
                "Alkermes plc"
            ],
            "summary": "Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.905476"
                }
            ],
            "overall_sentiment_score": 0.16266,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MURA",
                    "relevance_score": "0.015412",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALKS",
                    "relevance_score": "0.343175",
                    "ticker_sentiment_score": "0.036906",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMGTF",
                    "relevance_score": "0.015412",
                    "ticker_sentiment_score": "0.006869",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.015412",
                    "ticker_sentiment_score": "0.155303",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.015412",
                    "ticker_sentiment_score": "-0.02066",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.015412",
                    "ticker_sentiment_score": "-0.02066",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara®  ( ustekinumab ) ",
            "url": "https://www.globenewswire.com/news-release/2024/02/15/2829780/0/en/Alvotech-Announces-Expected-Global-Market-Entry-Dates-for-AVT04-Biosimilar-to-Stelara-ustekinumab.html",
            "time_published": "20240215T113000",
            "authors": [
                "Alvotech"
            ],
            "summary": "Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has reached settlement agreements with Johnson & Johnson in Japan, Canada and in the European Economic Area ( EEA ) for ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.104003,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ALVO",
                    "relevance_score": "0.536148",
                    "ticker_sentiment_score": "0.161299",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TEVA",
                    "relevance_score": "0.026562",
                    "ticker_sentiment_score": "0.059635",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KMDA",
                    "relevance_score": "0.026562",
                    "ticker_sentiment_score": "0.059635",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LTUS",
                    "relevance_score": "0.026562",
                    "ticker_sentiment_score": "0.059635",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.053094",
                    "ticker_sentiment_score": "0.105829",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara®  ( ustekinumab ) ",
            "url": "https://www.globenewswire.com/news-release/2024/02/15/2829779/0/en/Alvotech-Announces-Expected-Global-Market-Entry-Dates-for-AVT04-Biosimilar-to-Stelara-ustekinumab.html",
            "time_published": "20240215T113000",
            "authors": [
                "Alvotech"
            ],
            "summary": "REYKJAVIK, Iceland, Feb. 15, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has reached settlement agreements with Johnson & Johnson in Japan, ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.103994,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ALVO",
                    "relevance_score": "0.533678",
                    "ticker_sentiment_score": "0.160848",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TEVA",
                    "relevance_score": "0.026415",
                    "ticker_sentiment_score": "0.059586",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KMDA",
                    "relevance_score": "0.026415",
                    "ticker_sentiment_score": "0.059586",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LTUS",
                    "relevance_score": "0.026415",
                    "ticker_sentiment_score": "0.059586",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.052801",
                    "ticker_sentiment_score": "0.100797",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara®  ( ustekinumab )  - Alvotech  ( NASDAQ:ALVO ) ",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37152906/alvotech-announces-expected-global-market-entry-dates-for-avt04-biosimilar-to-stelara-ustekinumab",
            "time_published": "20240215T113000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "REYKJAVIK, Iceland, Feb. 15, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ALVO, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has reached settlement agreements with Johnson & Johnson in Japan, Canada and in ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.096748,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ALVO",
                    "relevance_score": "0.546745",
                    "ticker_sentiment_score": "0.153016",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TEVA",
                    "relevance_score": "0.026013",
                    "ticker_sentiment_score": "0.051022",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KMDA",
                    "relevance_score": "0.026013",
                    "ticker_sentiment_score": "0.051022",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LTUS",
                    "relevance_score": "0.026013",
                    "ticker_sentiment_score": "0.051022",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.051999",
                    "ticker_sentiment_score": "0.097722",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Evolution Health Group appoints Chris Mycek as Vice President, Enterprise Solutions - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/evolution-health-group-appoints-chris-mycek-as-vice-president-enterprise-solutions-302062372.html",
            "time_published": "20240215T111500",
            "authors": [],
            "summary": "Evolution Health Group appoints Chris Mycek as Vice President, Enterprise Solutions PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.362325,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CTSH",
                    "relevance_score": "0.082111",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.082111",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "David Einhorn's Greenlight Capital adds Kenvue, ETFs and exits Southwestern Energy",
            "url": "https://www.marketwatch.com/story/david-einhorns-greenlight-capital-adds-kenvue-etfs-and-exits-southwestern-energy-47937929",
            "time_published": "20240214T233800",
            "authors": [
                "Joy Wiltermuth"
            ],
            "summary": "Greenlight Capital picks up a new stake in Kenvue Inc, formerly the consumer healthcare division of Johnson & Johnson.",
            "banner_image": "https://images.mktw.net/im-790959/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.007016,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.904419",
                    "ticker_sentiment_score": "0.012492",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.733479",
                    "ticker_sentiment_score": "-0.22896",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "TEVA",
                    "relevance_score": "0.733479",
                    "ticker_sentiment_score": "0.199695",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Genmab Publishes 2023 Annual Report",
            "url": "https://www.globenewswire.com/news-release/2024/02/14/2829266/0/en/Genmab-Publishes-2023-Annual-Report.html",
            "time_published": "20240214T160200",
            "authors": [
                "Genmab A/S"
            ],
            "summary": "Company Announcement ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": 0.134216,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GMAB",
                    "relevance_score": "0.417611",
                    "ticker_sentiment_score": "0.145663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.024372",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ZLAB",
                    "relevance_score": "0.024372",
                    "ticker_sentiment_score": "0.02372",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.024372",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.097259",
                    "ticker_sentiment_score": "0.077179",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARGX",
                    "relevance_score": "0.024372",
                    "ticker_sentiment_score": "0.083727",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HALO",
                    "relevance_score": "0.024372",
                    "ticker_sentiment_score": "0.017036",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.121404",
                    "ticker_sentiment_score": "0.088215",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BNTX",
                    "relevance_score": "0.024372",
                    "ticker_sentiment_score": "0.083727",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More",
            "url": "https://www.zacks.com/stock/news/2226283/drug-biotech-stock-q4-earnings-due-on-feb-15-alny-bpmc-more",
            "time_published": "20240214T151200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Let's look at five biotech/drug companies, ALNY, BPMC, AGIO, CORT and RARE, slated to release quarterly results on Feb 15.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.120839,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CORT",
                    "relevance_score": "0.159834",
                    "ticker_sentiment_score": "0.056556",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AGIO",
                    "relevance_score": "0.199037",
                    "ticker_sentiment_score": "0.117008",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RARE",
                    "relevance_score": "0.159834",
                    "ticker_sentiment_score": "-0.078734",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.040212",
                    "ticker_sentiment_score": "0.26205",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ALNY",
                    "relevance_score": "0.159834",
                    "ticker_sentiment_score": "0.057876",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BPMC",
                    "relevance_score": "0.237745",
                    "ticker_sentiment_score": "0.139837",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.040212",
                    "ticker_sentiment_score": "-0.237683",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Should iShares Core High Dividend ETF  ( HDV )  Be on Your Investing Radar?",
            "url": "https://www.zacks.com/stock/news/2225919/should-ishares-core-high-dividend-etf-hdv-be-on-your-investing-radar",
            "time_published": "20240214T112003",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Style Box ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default178.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.242251,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.060694",
                    "ticker_sentiment_score": "0.117008",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MORN",
                    "relevance_score": "0.121037",
                    "ticker_sentiment_score": "0.193897",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VZ",
                    "relevance_score": "0.121037",
                    "ticker_sentiment_score": "0.068013",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.121037",
                    "ticker_sentiment_score": "0.068013",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.121037",
                    "ticker_sentiment_score": "0.068013",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Small Cell Lung Cancer Therapeutics Market To Witness Rapid Growth, Surpassing $10 Billion By 2028 As Per The Business Research Company's Small Cell Lung Cancer Therapeutics Global Market Report 2024",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37099046/small-cell-lung-cancer-therapeutics-market-to-witness-rapid-growth-surpassing-10-billion-by-2028-a",
            "time_published": "20240213T163000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "LONDON, Feb. 13, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's small cell lung cancer therapeutics global market report 2024, the small cell lung cancer therapeutics market is poised for remarkable growth.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.002457,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "A",
                    "relevance_score": "0.060236",
                    "ticker_sentiment_score": "0.019125",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GTHX",
                    "relevance_score": "0.060236",
                    "ticker_sentiment_score": "0.019125",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.060236",
                    "ticker_sentiment_score": "0.019125",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.060236",
                    "ticker_sentiment_score": "0.019125",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Federal judge tosses lobbying group's lawsuit challenging Medicare drug price negotiations",
            "url": "https://www.cnbc.com/2024/02/13/medicare-drug-price-negotiations-judge-tosses-phrma-lawsuit.html",
            "time_published": "20240213T162830",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "The decision is an early win for the Biden administration as it grapples with other legal challenges to the Inflation Reduction Act's Medicare price talks.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107130655-1665090556176-gettyimages-1431082899-_m021740_4b5641b7-17d1-48f7-8db3-6aef2e513b99.jpeg?v=1707837044&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.143508,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "PFE",
                    "relevance_score": "0.069495",
                    "ticker_sentiment_score": "-0.110869",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.069495",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.069495",
                    "ticker_sentiment_score": "-0.110869",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Gene Delivery System Market Size to Touch Around USD 10.0 billion, at a CAGR of 7.2% from 2023 to 2031: Report by Transparency Market Research, Inc.",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37096872/gene-delivery-system-market-size-to-touch-around-usd-10-0-billion-at-a-cagr-of-7-2-from-2023-to-20",
            "time_published": "20240213T152500",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Wilmington, Delaware, United States, Feb. 13, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global gene delivery system market is estimated to flourish at a CAGR of 7.2% from 2023 to 2031.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.376665,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SGMO",
                    "relevance_score": "0.03399",
                    "ticker_sentiment_score": "0.267177",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.03399",
                    "ticker_sentiment_score": "0.04987",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GNNSF",
                    "relevance_score": "0.03399",
                    "ticker_sentiment_score": "0.181458",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.03399",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TMO",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "0.30534",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "OXBDF",
                    "relevance_score": "0.168726",
                    "ticker_sentiment_score": "0.322112",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.03399",
                    "ticker_sentiment_score": "0.139717",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMGTF",
                    "relevance_score": "0.101725",
                    "ticker_sentiment_score": "0.078237",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "This $674 Million Deal Aims To Turn Your Body's Garbage Disposal Into A Disease Fighter",
            "url": "https://www.forbes.com/sites/alexknapp/2024/02/13/this-674-million-deal-aims-to-turn-your-bodys-garbage-disposal-into-a-disease-fighter/",
            "time_published": "20240213T120000",
            "authors": [
                "Alex Knapp"
            ],
            "summary": "he cellular processes that keep us alive produce a lot of waste. Which is why our cells have evolved a natural garbage disposal system, a group of special chemicals called \"protein degraders\" that break down unneeded junk in your body.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65c657baa5622357b682f2d8/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.167234,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BPMC",
                    "relevance_score": "0.047278",
                    "ticker_sentiment_score": "0.075969",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WM",
                    "relevance_score": "0.047278",
                    "ticker_sentiment_score": "-0.032024",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.141171",
                    "ticker_sentiment_score": "0.08369",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.047278",
                    "ticker_sentiment_score": "0.075969",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors - Cingulate  ( NASDAQ:CING ) , IMAC Hldgs  ( NASDAQ:BACK ) ",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37089299/cingulate-appoints-jay-roberts-bryan-lawrence-and-jeff-ervin-to-its-board-of-directors",
            "time_published": "20240213T114500",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "KANSAS CITY, Kan., Feb. 13, 2024 ( GLOBE NEWSWIRE ) -- Cingulate Inc.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.11557,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CING",
                    "relevance_score": "0.341342",
                    "ticker_sentiment_score": "0.029607",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BACK",
                    "relevance_score": "0.095899",
                    "ticker_sentiment_score": "0.07664",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VYNT",
                    "relevance_score": "0.032035",
                    "ticker_sentiment_score": "0.047518",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.064018",
                    "ticker_sentiment_score": "0.223442",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors",
            "url": "https://www.globenewswire.com/news-release/2024/02/13/2828084/0/en/Cingulate-Appoints-Jay-Roberts-Bryan-Lawrence-and-Jeff-Ervin-to-its-Board-of-Directors.html",
            "time_published": "20240213T114500",
            "authors": [
                "Cingulate Inc."
            ],
            "summary": "Announcement Follows Recent Public Offering and Successful Capital Raising Activity Announcement Follows Recent Public Offering and Successful Capital Raising Activity ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/61f4cd24-74d3-4103-b8f8-a768ef66e0ec",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.972756"
                }
            ],
            "overall_sentiment_score": 0.134082,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CING",
                    "relevance_score": "0.24316",
                    "ticker_sentiment_score": "0.037754",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BACK",
                    "relevance_score": "0.082204",
                    "ticker_sentiment_score": "0.076474",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VYNT",
                    "relevance_score": "0.027445",
                    "ticker_sentiment_score": "0.048191",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.054857",
                    "ticker_sentiment_score": "0.222931",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Should You Invest in the iShares U.S. Pharmaceuticals ETF  ( IHE ) ?",
            "url": "https://www.zacks.com/stock/news/2225205/should-you-invest-in-the-ishares-us-pharmaceuticals-etf-ihe",
            "time_published": "20240213T112007",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sector ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default7.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.215642,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.068306",
                    "ticker_sentiment_score": "0.032068",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.136113",
                    "ticker_sentiment_score": "0.064698",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ZTS",
                    "relevance_score": "0.136113",
                    "ticker_sentiment_score": "0.064698",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.136113",
                    "ticker_sentiment_score": "0.044001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.136113",
                    "ticker_sentiment_score": "0.064698",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Should You Invest in the Fidelity MSCI Health Care Index ETF  ( FHLC ) ?",
            "url": "https://www.zacks.com/stock/news/2225206/should-you-invest-in-the-fidelity-msci-health-care-index-etf-fhlc",
            "time_published": "20240213T112007",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sector ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default195.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.331073,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.130217",
                    "ticker_sentiment_score": "0.050334",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.130217",
                    "ticker_sentiment_score": "0.050334",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.130217",
                    "ticker_sentiment_score": "0.050334",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "RTX Stock: Bull vs. Bear",
            "url": "https://www.fool.com/investing/2024/02/13/rtx-stock-bull-vs-bear/",
            "time_published": "20240213T104700",
            "authors": [
                "Scott Levine and Lee Samaha"
            ],
            "summary": "Clouds are on the horizon for RTX, but do they mean the stock's not worth buying?",
            "banner_image": "https://g.foolcdn.com/editorial/images/763703/a-silver-bull-and-bear-on-a-financial-chart.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.20964,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LMT",
                    "relevance_score": "0.04912",
                    "ticker_sentiment_score": "0.050997",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.04912",
                    "ticker_sentiment_score": "0.050997",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.04912",
                    "ticker_sentiment_score": "-0.027013",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Dow Stocks You Can Confidently Buy Now and Hold Forever",
            "url": "https://www.fool.com/investing/2024/02/13/3-dow-stocks-you-can-buy-now-and-hold-forever/",
            "time_published": "20240213T102100",
            "authors": [
                "Sean Williams"
            ],
            "summary": "Three highly profitable, time-tested Dow components have the necessary tools to make their patient shareholders notably richer.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764927%2Fstock-chart-quote-bear-bull-trading-invest-short-options-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.795202"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.190704,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AXP",
                    "relevance_score": "0.035502",
                    "ticker_sentiment_score": "0.032642",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.035502",
                    "ticker_sentiment_score": "0.135904",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TWOH",
                    "relevance_score": "0.035502",
                    "ticker_sentiment_score": "0.18071",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.035502",
                    "ticker_sentiment_score": "-0.030169",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "V",
                    "relevance_score": "0.343755",
                    "ticker_sentiment_score": "0.233522",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.176116",
                    "ticker_sentiment_score": "0.058933",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Court dismisses pharmaceutical group's lawsuit over Medicare drug price programme",
            "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/court-dismisses-pharmaceutical-groups-lawsuit-over-medicare-drug-price-programme/3392958/",
            "time_published": "20240213T100238",
            "authors": [
                "Health Desk"
            ],
            "summary": "A federal judge has dismissed a lawsuit by the Pharmaceutical Research and Manufacturers of America ( PhRMA ) challenging a new program that allows Medicare to negotiate prices with drug companies for selected costly drugs. According to a report by news agency Reuters, U.S.",
            "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/02/painkillers-g0651a5da2_1920.jpg",
            "source": "The Financial Express",
            "category_within_source": "n/a",
            "source_domain": "www.financialexpress.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.218278,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.097457",
                    "ticker_sentiment_score": "-0.155529",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.097457",
                    "ticker_sentiment_score": "-0.155529",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors",
            "url": "https://www.globenewswire.com/news-release/2024/02/12/2827878/0/en/Connect-Biopharma-Appoints-Industry-Veteran-James-Huang-to-Board-of-Directors.html",
            "time_published": "20240212T213000",
            "authors": [
                "Connect Biopharma Holdings Limited"
            ],
            "summary": "SAN DIEGO, CA and TAICANG, China, Feb. 12, 2024 ( GLOBE NEWSWIRE ) -- Connect Biopharma Holdings Limited ( Nasdaq: CNTB ) ( \"Connect Biopharma\" or the \"Company\" ) , a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/6aecdeaf-3bef-4a9b-ba75-921c3ce2b6a5",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.152993,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CNTB",
                    "relevance_score": "0.330102",
                    "ticker_sentiment_score": "0.111969",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.042496",
                    "ticker_sentiment_score": "0.06721",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.042496",
                    "ticker_sentiment_score": "0.06721",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors - Connect Biopharma Hldgs  ( NASDAQ:CNTB ) ",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37080173/connect-biopharma-appoints-industry-veteran-james-huang-to-board-of-directors",
            "time_published": "20240212T213000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "James Huang brings over 30 years of biotech experience as a successful entrepreneur, investor and key opinion leader in the healthcare sector",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.145825,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CNTB",
                    "relevance_score": "0.323608",
                    "ticker_sentiment_score": "0.107821",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.04161",
                    "ticker_sentiment_score": "0.064093",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.04161",
                    "ticker_sentiment_score": "0.064093",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "A Look at Pharma ETFs After Q4 Earnings",
            "url": "https://www.zacks.com/stock/news/2224986/a-look-at-pharma-etfs-after-q4-earnings",
            "time_published": "20240212T175900",
            "authors": [
                "Sweta Killa"
            ],
            "summary": "The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default282.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999996"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.054971,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.082251",
                    "ticker_sentiment_score": "0.071368",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.123104",
                    "ticker_sentiment_score": "0.058563",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.082251",
                    "ticker_sentiment_score": "-0.003144",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.123104",
                    "ticker_sentiment_score": "0.110586",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Infinite Reality, the Global Leader in Immersive Experiences, Acquires Spatial Web Pioneer Ethereal Engine - Newbury Street Acq  ( NASDAQ:NBST ) , Greenidge Generation Hldg  ( NASDAQ:GREE ) ",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37068471/infinite-reality-the-global-leader-in-immersive-experiences-acquires-spatial-web-pioneer-ethereal-",
            "time_published": "20240212T140021",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Virtual Experiences Leader Acquires Ethereal Engine in Share-For-Share Transaction Valuing Infinite Reality at $2.5 Billion and Ethereal Engine at $75 million Entire Ethereal Engine Team, Including Top Executives and Innovators, Has Joined Infinite Reality",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "Mergers",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.314462,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NBST",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GREEL",
                    "relevance_score": "0.045655",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.045655",
                    "ticker_sentiment_score": "0.121313",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?",
            "url": "https://www.fool.com/investing/2024/02/12/is-it-too-late-to-buy-these-2-brilliant-passive-in/",
            "time_published": "20240212T123000",
            "authors": [
                "Rachel Warren"
            ],
            "summary": "These incredible businesses have long histories of successes behind them, and more to come.",
            "banner_image": "https://g.foolcdn.com/editorial/images/764307/getty-couple-happy-in-kitchen.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.210293,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GLDAF",
                    "relevance_score": "0.04028",
                    "ticker_sentiment_score": "-0.022456",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.04028",
                    "ticker_sentiment_score": "0.072597",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CERE",
                    "relevance_score": "0.04028",
                    "ticker_sentiment_score": "0.041031",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.276313",
                    "ticker_sentiment_score": "0.123407",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.313817",
                    "ticker_sentiment_score": "0.154311",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Cancer Supportive Care Drugs Market to be Worth USD 16.7 billion by 2031, Advancing at a 1.7% CAGR |Exclusive Report by Transparency Market Research, Inc.",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37064317/cancer-supportive-care-drugs-market-to-be-worth-usd-16-7-billion-by-2031-advancing-at-a-1-7-cagr-e",
            "time_published": "20240212T114728",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Wilmington, Delaware, United States, Feb. 12, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global cancer supportive care drugs market was projected to attain US$ 14.3 billion in 2022.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.076884,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.036926",
                    "ticker_sentiment_score": "0.050513",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMGTF",
                    "relevance_score": "0.110462",
                    "ticker_sentiment_score": "0.053449",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HRTX",
                    "relevance_score": "0.036926",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IUGNF",
                    "relevance_score": "0.036926",
                    "ticker_sentiment_score": "0.074185",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.036926",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "How Samuel Alito Became The Second-Richest Supreme Court Justice",
            "url": "https://www.forbes.com/sites/kylemullins/2024/02/12/how-samuel-alito-became-the-second-richest-supreme-court-justice/",
            "time_published": "20240212T113000",
            "authors": [
                "Kyle Mullins"
            ],
            "summary": "How Much Is Supreme Court Justice Samuel Alito Worth? Forbes ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65c682ca302c8646e809935a/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.130333,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "COP",
                    "relevance_score": "0.022389",
                    "ticker_sentiment_score": "0.083472",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.022389",
                    "ticker_sentiment_score": "0.083472",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.022389",
                    "ticker_sentiment_score": "0.053838",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights Johnson & Johnson, Disney, Uber, Goldman Sachs and Elevance Health",
            "url": "https://www.zacks.com/stock/news/2224450/the-zacks-analyst-blog-highlights-johnson-johnson-disney-uber-goldman-sachs-and-elevance-health",
            "time_published": "20240212T110000",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "Johnson & Johnson, Disney, Uber, Goldman Sachs and Elevance Health are included in this Analyst Blog.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f6/446.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.267274,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.064623",
                    "ticker_sentiment_score": "0.0335",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.038396",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.373378",
                    "ticker_sentiment_score": "0.23186",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ELV",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.038396",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DIS",
                    "relevance_score": "0.192183",
                    "ticker_sentiment_score": "0.049362",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.254307",
                    "ticker_sentiment_score": "0.047748",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Top Research Reports for Johnson & Johnson, Walt Disney & Uber",
            "url": "https://www.zacks.com/research-daily/2223994/top-research-reports-for-johnson-johnson-walt-disney-uber",
            "time_published": "20240209T214200",
            "authors": [
                "Mark Vickery"
            ],
            "summary": "Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), The Walt Disney Company (DIS) and Uber Technologies, Inc. (UBER).",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cf/2435.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.319902,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.087185",
                    "ticker_sentiment_score": "0.035317",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.257442",
                    "ticker_sentiment_score": "0.262544",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.087185",
                    "ticker_sentiment_score": "0.011657",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What to think about 'Peak 65'",
            "url": "https://www.marketwatch.com/story/what-to-think-about-peak-65-d23f2413",
            "time_published": "20240209T190600",
            "authors": [
                "Philip van Doorn"
            ],
            "summary": "Also: Strategies to build a retirement nest egg and make it last, and a different way for investors to play the weight-loss-drug craze.",
            "banner_image": "https://images.mktw.net/im-74524387?width=700&height=486",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.992549"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.714479"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.095345,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.085936",
                    "ticker_sentiment_score": "0.071851",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.04303",
                    "ticker_sentiment_score": "0.012989",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.128592",
                    "ticker_sentiment_score": "-0.025551",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.085936",
                    "ticker_sentiment_score": "-0.062043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.128592",
                    "ticker_sentiment_score": "0.022061",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WEWOW",
                    "relevance_score": "0.04303",
                    "ticker_sentiment_score": "0.093845",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NYCB",
                    "relevance_score": "0.085936",
                    "ticker_sentiment_score": "-0.045374",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.085936",
                    "ticker_sentiment_score": "-0.062043",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Is Illumina Stock Trading Lower Today? - Illumina  ( NASDAQ:ILMN ) ",
            "url": "https://www.benzinga.com/news/earnings/24/02/37034941/dna-sequencing-kit-provider-illuminas-q4-earnings-edge-above-street-estimates-works-to-resolve-grai",
            "time_published": "20240209T143218",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Thursday, Illumina Inc ILMN reported fourth-quarter 2023 sales of $1.12 billion, up 4% Y/Y, beating the consensus of $1.09 billion. The company reported adjusted EPS of $0.14, surpassing the consensus estimate of $0.02.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/ILMN.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.285694,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ILMN",
                    "relevance_score": "0.917585",
                    "ticker_sentiment_score": "0.56318",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.247838",
                    "ticker_sentiment_score": "0.334873",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare - Johnson & Johnson  ( NYSE:JNJ ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
            "url": "https://www.benzinga.com/markets/cannabis/24/02/37034215/bernie-sanders-blasts-big-pharmas-pricing-of-lifesaving-drugs-in-us-during-senate-hearing-on-med",
            "time_published": "20240209T141014",
            "authors": [
                "Nina Zdinjak"
            ],
            "summary": "CEOs of Johnson & Johnson JNJ, Merck MRK and Bristol-Myers Squibb BMY defended the high prices of their drugs as they were grilled by the Senate Health Committee, led by Senator Bernie Sanders who submitted a report blasting the extravagant cost of three drugs.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/New-York--Usa---April-14--2016-President.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.105557,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NYT",
                    "relevance_score": "0.063258",
                    "ticker_sentiment_score": "0.024376",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SSTK",
                    "relevance_score": "0.063258",
                    "ticker_sentiment_score": "0.294697",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.126119",
                    "ticker_sentiment_score": "-0.103185",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.126119",
                    "ticker_sentiment_score": "-0.103185",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson  ( JNJ )  is Attracting Investor Attention: Here is What You Should Know",
            "url": "https://www.zacks.com/stock/news/2223976/johnson-johnson-jnj-is-attracting-investor-attention-here-is-what-you-should-know",
            "time_published": "20240209T140011",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default345.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999999"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.230814,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.481177",
                    "ticker_sentiment_score": "0.14001",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "5 things to know for Feb. 9: Presidential race, Prescription drugs, Vladimir Putin, Red Sea, Volcano eruption",
            "url": "https://www.cnn.com/2024/02/09/us/5-things-to-know-for-feb-9-presidential-race-prescription-drugs-vladimir-putin-red-sea-volcano-eruption/index.html",
            "time_published": "20240209T115300",
            "authors": [
                "Alexandra Banner"
            ],
            "summary": "Astronomers have discovered a potentially habitable \"super-Earth\" around 137 light-years away. Its estimated size is one and a half times as wide as our planet, and research shows it may be able to hold the right temperature for liquid water to exist on its surface.",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/240209020548-jill-dougherty-vladimir-putin-2.jpg?c=16x9&q=w_850,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.012203,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.034381",
                    "ticker_sentiment_score": "-0.231789",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "FOX",
                    "relevance_score": "0.034381",
                    "ticker_sentiment_score": "-0.057699",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.034381",
                    "ticker_sentiment_score": "0.035347",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.034381",
                    "ticker_sentiment_score": "0.035347",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ophthalmology Surgical Devices Market Size Estimated to Reach USD 12.1 billion, Rising at a CAGR of 4.7% by 2031: Transparency Market Research, Inc.",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37028724/ophthalmology-surgical-devices-market-size-estimated-to-reach-usd-12-1-billion-rising-at-a-cagr-of",
            "time_published": "20240209T093000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Wilmington, Delaware, United States, Feb. 09, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global ophthalmology surgical devices market is estimated to flourish at a CAGR of 4.7% from 2023 to 2031.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.382076,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.03545",
                    "ticker_sentiment_score": "0.050198",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.10607",
                    "ticker_sentiment_score": "0.215386",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "STAA",
                    "relevance_score": "0.03545",
                    "ticker_sentiment_score": "0.420624",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "ALC",
                    "relevance_score": "0.07083",
                    "ticker_sentiment_score": "0.176899",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BLCO",
                    "relevance_score": "0.07083",
                    "ticker_sentiment_score": "0.176899",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GKOS",
                    "relevance_score": "0.03545",
                    "ticker_sentiment_score": "0.369733",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "HOCPF",
                    "relevance_score": "0.07083",
                    "ticker_sentiment_score": "0.144236",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IRIX",
                    "relevance_score": "0.03545",
                    "ticker_sentiment_score": "0.193516",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TOPCF",
                    "relevance_score": "0.03545",
                    "ticker_sentiment_score": "0.175472",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMGTF",
                    "relevance_score": "0.10607",
                    "ticker_sentiment_score": "0.099956",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.03545",
                    "ticker_sentiment_score": "0.175472",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Senate panel grills pharmaceutical CEOs on drug prices: 'You bear a measure of responsibility'",
            "url": "https://www.cnn.com/2024/02/08/health/senate-hearing-drug-prices/index.html",
            "time_published": "20240209T001800",
            "authors": [
                "Jacqueline Howard"
            ],
            "summary": "US senators and pharmaceutical CEOs faced off in a hearing Thursday about why prescription drugs have higher price tags in the United States than in other nations.",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/2024-01-29t162708z-699916914-rc2rr5a8hwzx-rtrmadp-3-health-usa-drugpricing.JPG?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.111311,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.027226",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.108589",
                    "ticker_sentiment_score": "0.084372",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.081552",
                    "ticker_sentiment_score": "0.050203",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharma CEOs asked to defend high drug prices at Senate hearing - .com",
            "url": "https://www.upi.com/Top_News/US/2024/02/08/drug-prices-Senate-hearing/7771707428395/",
            "time_published": "20240208T220136",
            "authors": [],
            "summary": "Pharma CEOs asked to defend high drug prices at Senate hearing UPI News ...",
            "banner_image": "https://cdnph.upi.com/sv/ph/og/upi/7771707428395/2024/1/857e49d70155a011669b16c949edcc64/v1.5/Pharma-CEOs-asked-to-defend-high-drug-prices-at-Senate-hearing.jpg",
            "source": "UPI Business",
            "category_within_source": "n/a",
            "source_domain": "www.upi.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.088952,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BMY",
                    "relevance_score": "0.22595",
                    "ticker_sentiment_score": "0.014433",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.114137",
                    "ticker_sentiment_score": "0.064201",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharma Stocks: 5 Biggest Companies in 2024",
            "url": "https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/top-10-pharmaceutical-companies/",
            "time_published": "20240208T211500",
            "authors": [
                "Meagen Seatter"
            ],
            "summary": "Companies in this sector are constantly researching and creating innovative treatments for various medical conditions, including immuno-oncology, neurology and rare diseases. In recent years, there has been a particular focus on developing new treatments for diabetes, weight loss and cancer.",
            "banner_image": "https://investingnews.com/media-library/pills-spilling-out-of-a-pill-bottle-on-a-yellow-background.jpg?id=32933343&width=1200&height=800&quality=85&coordinates=65%2C0%2C66%2C0",
            "source": "Investing News Network",
            "category_within_source": "n/a",
            "source_domain": "investingnews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938793"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.129917,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.02118",
                    "ticker_sentiment_score": "0.038373",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.02118",
                    "ticker_sentiment_score": "0.045406",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.042346",
                    "ticker_sentiment_score": "0.083975",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.042346",
                    "ticker_sentiment_score": "0.070123",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.042346",
                    "ticker_sentiment_score": "0.089865",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAH",
                    "relevance_score": "0.02118",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.02118",
                    "ticker_sentiment_score": "0.111754",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "J&J, Merck and Bristol Myers CEOs, under fire on Capitol Hill, seek to turn up heat on drug-market middlemen",
            "url": "https://www.marketwatch.com/story/j-j-merck-and-bristol-myers-ceos-under-fire-on-capitol-hill-seek-to-turn-up-heat-on-drug-market-middlemen-abe1fc39",
            "time_published": "20240208T202900",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "Drugmakers grilled on the cost of prescription drugs on Capitol Hill Thursday sought to deflect the criticism onto drug-market middlemen who they said are pushing list prices for medications higher.",
            "banner_image": "https://images.mktw.net/im-48673845/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.076256,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BMY",
                    "relevance_score": "0.100588",
                    "ticker_sentiment_score": "0.008637",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.100588",
                    "ticker_sentiment_score": "-0.039635",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Kenvue  ( KVUE )  Q4 2023 Earnings Call Transcript",
            "url": "https://www.fool.com/earnings/call-transcripts/2024/02/08/kenvue-kvue-q4-2023-earnings-call-transcript/",
            "time_published": "20240208T164514",
            "authors": [
                "Motley Fool Transcribing"
            ],
            "summary": "KVUE earnings call for the period ending December 31, 2023.",
            "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.332108,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.062434",
                    "ticker_sentiment_score": "0.164256",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.005208",
                    "ticker_sentiment_score": "0.203606",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.005208",
                    "ticker_sentiment_score": "0.203606",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CCORF",
                    "relevance_score": "0.005208",
                    "ticker_sentiment_score": "0.140894",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.015623",
                    "ticker_sentiment_score": "0.143136",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "If Bernie Sanders is right about Big Pharma, why are the stocks doing so badly?",
            "url": "https://www.marketwatch.com/story/if-bernie-sanders-is-right-about-big-pharma-why-are-the-stocks-doing-so-badly-d7b07454",
            "time_published": "20240208T164500",
            "authors": [
                "Brett Arends"
            ],
            "summary": "Making money by investing in pharmaceutical companies isn't as easy as you might think.",
            "banner_image": "https://images.mktw.net/im-19753548/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.024123,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BMY",
                    "relevance_score": "0.12546",
                    "ticker_sentiment_score": "0.013304",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.166743",
                    "ticker_sentiment_score": "0.015749",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's Why You Should Invest in Boston Scientific  ( BSX )  Now",
            "url": "https://www.zacks.com/stock/news/2223513/heres-why-you-should-invest-in-boston-scientific-bsx-now",
            "time_published": "20240208T153400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Investors are optimistic about Boston Scientific (BSX) on strength across the target market and upbeat guidance.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999476"
                }
            ],
            "overall_sentiment_score": 0.275819,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "UHS",
                    "relevance_score": "0.20279",
                    "ticker_sentiment_score": "0.149944",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EW",
                    "relevance_score": "0.051221",
                    "ticker_sentiment_score": "0.090462",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNN",
                    "relevance_score": "0.051221",
                    "ticker_sentiment_score": "0.090462",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ITGR",
                    "relevance_score": "0.20279",
                    "ticker_sentiment_score": "0.073558",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.051221",
                    "ticker_sentiment_score": "0.090462",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.251941",
                    "ticker_sentiment_score": "0.246126",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.051221",
                    "ticker_sentiment_score": "0.090462",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.051221",
                    "ticker_sentiment_score": "0.090462",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.102231",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PXXXF",
                    "relevance_score": "0.102231",
                    "ticker_sentiment_score": "0.119803",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharma CEOs Will Testify Today Over Prescription Drug Prices: Here's What To Watch For",
            "url": "https://www.forbes.com/sites/tylerroush/2024/02/08/pharma-ceos-will-testify-today-over-prescription-drug-prices-heres-what-to-watch-for/",
            "time_published": "20240208T152829",
            "authors": [
                "Ty Roush"
            ],
            "summary": "Chief executives from three major pharmaceutical companies will testify before a Senate committee on Thursday, following a back-and-forth with Sen. Bernie Sanders ( I-Vt. ) , who has accused the firms of overcharging Americans for prescription drugs.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65c4f258ec6a6b22d51c0160/0x0.jpg?format=jpg&crop=3696,2078,x0,y378,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.0,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.152983",
                    "ticker_sentiment_score": "0.053732",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.076847",
                    "ticker_sentiment_score": "0.042438",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.076847",
                    "ticker_sentiment_score": "-0.008213",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.227716",
                    "ticker_sentiment_score": "-0.021698",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.076847",
                    "ticker_sentiment_score": "0.042438",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Global Acne Treatment Market Revenue is Estimated to Reach USD 9,138.04 million by 2031, Growing at a CAGR of 5.13%: Straits Research",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37010173/global-acne-treatment-market-revenue-is-estimated-to-reach-usd-9-138-04-million-by-2031-growing-at",
            "time_published": "20240208T151000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "New York, United States, Feb. 08, 2024 ( GLOBE NEWSWIRE ) -- Acne is a skin condition that results from clogged skin openings and pores, including hair follicles. Most people who tend to follow this order are teenagers and people in their early 20s.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.165401,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.038655",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VYNE",
                    "relevance_score": "0.038655",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CPPSF",
                    "relevance_score": "0.038655",
                    "ticker_sentiment_score": "0.186339",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SSKN",
                    "relevance_score": "0.038655",
                    "ticker_sentiment_score": "0.093637",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TRXPF",
                    "relevance_score": "0.038655",
                    "ticker_sentiment_score": "0.139792",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.038655",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TEVA",
                    "relevance_score": "0.038655",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BHC",
                    "relevance_score": "0.038655",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LBTSF",
                    "relevance_score": "0.038655",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Kenvue's stock slides 2.6% as J & J spinoff's revenue and guidance fall short of expectations",
            "url": "https://www.marketwatch.com/story/j-j-spinoff-kenvue-stock-loses-ground-as-profit-drops-ddbc804d",
            "time_published": "20240208T124100",
            "authors": [
                "Ciara Linnane",
                "Steve Gelsi"
            ],
            "summary": "The company said it will prioritize its U.S. skin-health and beauty business in 2024, and aim to reach more consumers and invest in its brands.",
            "banner_image": "https://images.mktw.net/im-775991/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928769"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.113362,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.362505",
                    "ticker_sentiment_score": "0.187614",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.246582",
                    "ticker_sentiment_score": "-0.066709",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Senators to question Merck, J&J and Bristol Myers Squibb CEOs over high U.S. drug pricing",
            "url": "https://www.cnbc.com/2024/02/08/jj-merck-bristol-myers-squibb-ceos-senate-drug-price-hearing.html",
            "time_published": "20240208T120001",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "The push to cut drug prices is one of those rare hot-button issues that unites the two major political parties.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107370419-1707331495916-gettyimages-1953244670-sanders_BC_183_012524JPG.jpeg?v=1707350713&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                }
            ],
            "overall_sentiment_score": 0.065922,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BABA",
                    "relevance_score": "0.043658",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.043658",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.415927",
                    "ticker_sentiment_score": "0.069353",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.087185",
                    "ticker_sentiment_score": "0.120631",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.043658",
                    "ticker_sentiment_score": "-0.130701",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Medical Device Technologies Market is Anticipated to Reach USD 662.7 billion by 2028: Transparency Market Research, Inc.",
            "url": "https://www.benzinga.com/pressreleases/24/02/g37004095/medical-device-technologies-market-is-anticipated-to-reach-usd-662-7-billion-by-2028-transparency-",
            "time_published": "20240208T120000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Wilmington, Delaware, United States, Feb. 08, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global medical device technologies market is estimated to flourish at a CAGR of 4.3% from 2021 to 2028.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.423859,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.031612",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "0.107762",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.031612",
                    "ticker_sentiment_score": "0.12322",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAH",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "0.317822",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "OCPNF",
                    "relevance_score": "0.031612",
                    "ticker_sentiment_score": "0.148981",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WLDS",
                    "relevance_score": "0.031612",
                    "ticker_sentiment_score": "0.145032",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMGTF",
                    "relevance_score": "0.094638",
                    "ticker_sentiment_score": "0.1079",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.031612",
                    "ticker_sentiment_score": "0.221755",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SNN",
                    "relevance_score": "0.031612",
                    "ticker_sentiment_score": "0.333601",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "0.193004",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.031612",
                    "ticker_sentiment_score": "0.333601",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TRUMF",
                    "relevance_score": "0.031612",
                    "ticker_sentiment_score": "0.148981",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAX",
                    "relevance_score": "0.031612",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.063174",
                    "ticker_sentiment_score": "0.193004",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Decabillionaire Dynasties: These Are The Richest Families In America",
            "url": "https://www.forbes.com/sites/mattdurot/2024/02/08/americas-richest-families-10-billion-waltons-mars-kochs-rockefeller-decabillionaire-dynasties/",
            "time_published": "20240208T113000",
            "authors": [
                "Matt Durot"
            ],
            "summary": "America's Richest Families 2024 Forbes ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65c3fda2ca7bdc4c0f3f7d05/0x0.jpg?format=jpg&crop=1920,1080,x0,y0,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.998356"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.142857"
                }
            ],
            "overall_sentiment_score": 0.094113,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DD",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "0.025415",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDNDF",
                    "relevance_score": "0.014537",
                    "ticker_sentiment_score": "0.038755",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SCU",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "-0.03251",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JOUT",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "-0.019945",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "0.026525",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "H",
                    "relevance_score": "0.029069",
                    "ticker_sentiment_score": "0.042992",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPG",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "0.016838",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "L",
                    "relevance_score": "0.021804",
                    "ticker_sentiment_score": "0.042007",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ITW",
                    "relevance_score": "0.014537",
                    "ticker_sentiment_score": "0.035689",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMGTF",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "0.025415",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RITM",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "-0.03251",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WLK",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "0.022102",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GD",
                    "relevance_score": "0.021804",
                    "ticker_sentiment_score": "-0.065217",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PSA",
                    "relevance_score": "0.014537",
                    "ticker_sentiment_score": "-0.040106",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AA",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "0.114061",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NTRS",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "0.033558",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "0.019167",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SYK",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "0.07316",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BF-A",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "0.019945",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "-0.003304",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BEN",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "-0.010896",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ZD",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "-0.03251",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ICNB",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "0.002327",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ROL",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "0.018047",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CPB",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "0.016164",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.014537",
                    "ticker_sentiment_score": "0.035689",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "0.058742",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MANU",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "0.01934",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTAS",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "-0.005586",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MAR",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "-0.035994",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.021804",
                    "ticker_sentiment_score": "0.103389",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.007269",
                    "ticker_sentiment_score": "0.083218",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Johnson & Johnson a Good Dividend Stock to Buy Now?",
            "url": "https://www.fool.com/investing/2024/02/08/is-johnson-johnson-a-good-dividend-stock-to-buy-no/",
            "time_published": "20240208T103700",
            "authors": [
                "Cory Renauer"
            ],
            "summary": "The healthcare conglomerate has been raising its dividend payout since Kennedy was president, but there have been some recent changes.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762920%2Finvestor-looking-for-stocks-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.459462"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.967321"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.122127,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.11894",
                    "ticker_sentiment_score": "0.0395",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CURN",
                    "relevance_score": "0.059636",
                    "ticker_sentiment_score": "-0.091999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.11894",
                    "ticker_sentiment_score": "0.056503",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.235252",
                    "ticker_sentiment_score": "0.219396",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Drug Delivery Systems Market is Set to Increase to USD 71.6 billion, Registering a 6.8 % CAGR from 2023 to 2031 | Report by Transparency Market Research, Inc.",
            "url": "https://www.benzinga.com/pressreleases/24/02/g36997902/drug-delivery-systems-market-is-set-to-increase-to-usd-71-6-billion-registering-a-6-8-cagr-from-20",
            "time_published": "20240208T023000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Wilmington, Delaware, United States, Feb. 07, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - Drug delivery systems were valued at US$ 40.1 billion in 2022. A CAGR of 6.8% is expected between 2023 and 2031, reaching US$ 71.6 billion by 2031.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.261837,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.033098",
                    "ticker_sentiment_score": "0.04966",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.033098",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.033098",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BDX",
                    "relevance_score": "0.033098",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.033098",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAX",
                    "relevance_score": "0.033098",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMGTF",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "0.10858",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.043048",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Energy-Based Aesthetic Devices Market to grow by USD 1.75 billion from 2022 to 2027, Alma Lasers GmbH, Bausch ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/energy-based-aesthetic-devices-market-to-grow-by-usd-1-75-billion-from-2022-to-2027--alma-lasers-gmbh-bausch-health-co-inc-and-candela-corp-are-key-companies--technavio-302056710.html",
            "time_published": "20240208T011200",
            "authors": [],
            "summary": "Energy-Based Aesthetic Devices Market to grow by USD 1.75 billion from 2022 to 2027, Alma Lasers GmbH, Bausch ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.259903,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "IRIX",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.044537",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VERO",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.044537",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CUTR",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.044537",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.044537",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BBAI, PGTI, AMAM, FGH",
            "url": "https://www.benzinga.com/pressreleases/24/02/g36996709/investigation-the-m-a-class-action-firm-continues-investigating-the-merger-bbai-pgti-amam-fgh",
            "time_published": "20240208T003403",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "NEW YORK, Feb. 07, 2024 ( GLOBE NEWSWIRE ) -- Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.839681"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.239163,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PGTI",
                    "relevance_score": "0.366061",
                    "ticker_sentiment_score": "0.356052",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "FGF",
                    "relevance_score": "0.188193",
                    "ticker_sentiment_score": "0.213212",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMAM",
                    "relevance_score": "0.366061",
                    "ticker_sentiment_score": "0.31508",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DOOR",
                    "relevance_score": "0.094762",
                    "ticker_sentiment_score": "0.153405",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.094762",
                    "ticker_sentiment_score": "0.134411",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Looking Into Johnson & Johnson's Recent Short Interest - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/insights/short-sellers/24/02/36991315/looking-into-johnson-johnsons-recent-short-interest",
            "time_published": "20240207T204525",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Johnson & Johnson's JNJ short percent of float has risen 19.23% since its last report. The company recently reported that it has 15.01 million shares sold short, which is 0.62% of all regular shares that are available for trading.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.265071,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.221819",
                    "ticker_sentiment_score": "0.15378",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "As Merck, J&J, Bristol Myers CEOs face drug-pricing questions, real problems remain under the radar, experts say",
            "url": "https://www.marketwatch.com/story/merck-j-j-and-bristol-myers-ceos-face-drug-pricing-grilling-on-capitol-hill-but-experts-cite-deeper-problems-under-the-radar-3bd4055f",
            "time_published": "20240207T190800",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "Lawmakers have emphasized gaps between U.S. list prices and overseas costs for a handful of drugs made by the three drugmakers.",
            "banner_image": "https://images.mktw.net/im-70733191/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.016523,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DTATF",
                    "relevance_score": "0.048523",
                    "ticker_sentiment_score": "0.083115",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.144853",
                    "ticker_sentiment_score": "0.051055",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.19231",
                    "ticker_sentiment_score": "0.061905",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The global hydrogel dressing market size, as forecasted by Straits Research, is poised to hit USD 996.75 million by 2031, experiencing substantial growth at a CAGR of 9.9%",
            "url": "https://www.benzinga.com/pressreleases/24/02/g36983967/the-global-hydrogel-dressing-market-size-as-forecasted-by-straits-research-is-poised-to-hit-usd-99",
            "time_published": "20240207T153000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "New York, United States, Feb. 07, 2024 ( GLOBE NEWSWIRE ) -- Hydrogel is an insoluble polymer chain network crucial in wound care due to its high moisture content, which prevents infections by inhibiting microbes.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.124153,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.03473",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNN",
                    "relevance_score": "0.069394",
                    "ticker_sentiment_score": "0.059986",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.069394",
                    "ticker_sentiment_score": "0.059986",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.069394",
                    "ticker_sentiment_score": "0.071166",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IART",
                    "relevance_score": "0.069394",
                    "ticker_sentiment_score": "0.071166",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NXGL",
                    "relevance_score": "0.03473",
                    "ticker_sentiment_score": "-0.024704",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MMM",
                    "relevance_score": "0.03473",
                    "ticker_sentiment_score": "-0.072045",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CLPBY",
                    "relevance_score": "0.03473",
                    "ticker_sentiment_score": "-0.072045",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.03473",
                    "ticker_sentiment_score": "0.176515",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CNVVF",
                    "relevance_score": "0.069394",
                    "ticker_sentiment_score": "0.071166",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Global Dental Floss Market Size is Estimated to Reach USD 955.21 Million by 2031, Growing at a CAGR of 4.96%: Straits Research",
            "url": "https://www.benzinga.com/pressreleases/24/02/g36983131/global-dental-floss-market-size-is-estimated-to-reach-usd-955-21-million-by-2031-growing-at-a-cagr",
            "time_published": "20240207T151000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "New York, United States, Feb. 07, 2024 ( GLOBE NEWSWIRE ) -- Flossing is a fundamental dental hygiene technique because it removes the plaque between teeth, significantly contributing to periodontal diseases.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.198651,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CL",
                    "relevance_score": "0.0367",
                    "ticker_sentiment_score": "0.046552",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LIOPF",
                    "relevance_score": "0.0367",
                    "ticker_sentiment_score": "0.046552",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.0367",
                    "ticker_sentiment_score": "0.046552",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PBH",
                    "relevance_score": "0.0367",
                    "ticker_sentiment_score": "0.046552",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.0367",
                    "ticker_sentiment_score": "0.046552",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PRGO",
                    "relevance_score": "0.0367",
                    "ticker_sentiment_score": "0.046552",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Arkuda Therapeutics Announces Option and Asset Purchase Agreement",
            "url": "https://www.prnewswire.com/news-releases/arkuda-therapeutics-announces-option-and-asset-purchase-agreement-302055075.html",
            "time_published": "20240207T120000",
            "authors": [
                "Arkuda Therapeutics"
            ],
            "summary": "- Arkuda to grant Janssen option to acquire Arkuda's portfolio of lysosomal function enhancers in exchange for upfront option payment and opportunity for additional milestone payments",
            "banner_image": "https://mma.prnewswire.com/media/2334811/Arkuda_Therapeutics_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.24302,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PFE",
                    "relevance_score": "0.12165",
                    "ticker_sentiment_score": "0.021866",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.240489",
                    "ticker_sentiment_score": "0.239986",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Is Johnson & Johnson Stock a Buy Now?",
            "url": "https://www.fool.com/investing/2024/02/07/is-johnson-johnson-stock-a-buy-now/",
            "time_published": "20240207T102500",
            "authors": [
                "Justin Pope"
            ],
            "summary": "Don't overlook this boring company's stellar reliability.",
            "banner_image": "https://g.foolcdn.com/editorial/images/763633/johnson_and_johnson_employee_with_beaker_and_logo_on_coat_jnj.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.997874"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.253773,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.119235",
                    "ticker_sentiment_score": "0.066764",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMAM",
                    "relevance_score": "0.059785",
                    "ticker_sentiment_score": "0.154009",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.451494",
                    "ticker_sentiment_score": "0.243495",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Cementless Total Knee Arthroplasty (TKA) Market is to grow by USD 2.40 billion from 2022 to 2027, Aesculap Implants ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/cementless-total-knee-arthroplasty-tka-market-is-to-grow-by-usd-2-40-billion-from-2022-to-2027--aesculap-implants-systems-llc-and-allegra-orthopaedics-ltd-are-among-the-key-companies--technavio-302055145.html",
            "time_published": "20240207T033600",
            "authors": [],
            "summary": "Cementless Total Knee Arthroplasty ( TKA ) Market is to grow by USD 2.40 billion from 2022 to 2027, Aesculap Implants ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.20276,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ZBH",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNN",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SYK",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CFMS",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MEDGF",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MCRPF",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "INVESTIGATION ALERT: Halper Sadeh LLC Investigates PGTI, FGH, AMAM - Ambrx Biopharma  ( NASDAQ:AMAM ) , FG Group Holdings  ( AMEX:FGH ) ",
            "url": "https://www.benzinga.com/pressreleases/24/02/g36971411/investigation-alert-halper-sadeh-llc-investigates-pgti-fgh-amam",
            "time_published": "20240207T022653",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "NEW YORK, Feb. 06, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: PGT Innovations, Inc.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.083378,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "PGTI",
                    "relevance_score": "0.137671",
                    "ticker_sentiment_score": "0.090541",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FGF",
                    "relevance_score": "0.271274",
                    "ticker_sentiment_score": "0.141792",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMAM",
                    "relevance_score": "0.137671",
                    "ticker_sentiment_score": "0.094182",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.137671",
                    "ticker_sentiment_score": "0.094182",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Embolization Coil Market to grow by USD 481.9 million from 2022 to 2027, Abbott Laboratories and Achieva Medical ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/embolization-coil-market-to-grow-by-usd-481-9-million-from-2022-to-2027---abbott-laboratories-and-achieva-medical-are-among-the-key-companies--technavio-302053633.html",
            "time_published": "20240206T223600",
            "authors": [],
            "summary": "Embolization Coil Market to grow by USD 481.9 million from 2022 to 2027, Abbott Laboratories and Achieva Medical ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.127694,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MMSI",
                    "relevance_score": "0.073321",
                    "ticker_sentiment_score": "0.04126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.146025",
                    "ticker_sentiment_score": "0.04477",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SYK",
                    "relevance_score": "0.073321",
                    "ticker_sentiment_score": "0.04126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.146025",
                    "ticker_sentiment_score": "0.063505",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TRUMF",
                    "relevance_score": "0.073321",
                    "ticker_sentiment_score": "0.04126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.073321",
                    "ticker_sentiment_score": "0.04126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PEN",
                    "relevance_score": "0.073321",
                    "ticker_sentiment_score": "0.04126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAH",
                    "relevance_score": "0.073321",
                    "ticker_sentiment_score": "0.04126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KANKF",
                    "relevance_score": "0.073321",
                    "ticker_sentiment_score": "0.04126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.073321",
                    "ticker_sentiment_score": "0.04126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MCRPF",
                    "relevance_score": "0.073321",
                    "ticker_sentiment_score": "0.04126",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "How Big Tech is Helping Leverage Big Data in Healthcare",
            "url": "https://investingnews.com/big-tech-healthcare/",
            "time_published": "20240206T211500",
            "authors": [
                "Meagen Seatter"
            ],
            "summary": "While experts agree that Big Tech has the potential to improve patient outcomes by revolutionizing the way illnesses are diagnosed and treated, there are also challenges and ethical considerations when implementing AI in healthcare.",
            "banner_image": "https://investingnews.com/media-library/male-doctor-holding-cell-phone.jpg?id=51396674&width=1200&height=800&quality=85&coordinates=0%2C0%2C0%2C0",
            "source": "Investing News Network",
            "category_within_source": "n/a",
            "source_domain": "investingnews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.251034,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "WLDS",
                    "relevance_score": "0.021978",
                    "ticker_sentiment_score": "0.131944",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.021978",
                    "ticker_sentiment_score": "0.047445",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "icotec Medical Appoints Christoph Eigenmann as New US CEO and Promotes Carter Lonsberry to Executive Chairman ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/icotec-medical-appoints-christoph-eigenmann-as-new-us-ceo-and-promotes-carter-lonsberry-to-executive-chairman-of-the-board-302055071.html",
            "time_published": "20240206T182700",
            "authors": [],
            "summary": "icotec Medical Appoints Christoph Eigenmann as New US CEO and Promotes Carter Lonsberry to Executive Chairman ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.452745,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.072217",
                    "ticker_sentiment_score": "0.214925",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Propelling Advances In Adrenal Cancer Diagnostics Market - Projected Market Size Of $180.09 Billion By 2028 As Per The Business Research Company's Adrenal Cancer Diagnostics Global Market Report 2024",
            "url": "https://www.benzinga.com/pressreleases/24/02/g36960048/propelling-advances-in-adrenal-cancer-diagnostics-market-projected-market-size-of-180-09-billion-b",
            "time_published": "20240206T163000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "LONDON, Feb. 06, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's research on the adrenal cancer diagnostics market, the adrenal cancer diagnostics market has witnessed robust growth, with the market size increasing from $130.84 billion in 2023 to $140.35 billion in 2024, ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.121979,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.063258",
                    "ticker_sentiment_score": "0.102537",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Bristol Myers  ( BMY ) , TSVT CAR T-Cell Therapy to Face FDA's ODAC",
            "url": "https://www.zacks.com/stock/news/2221922/bristol-myers-bmy-tsvt-car-t-cell-therapy-to-face-fdas-odac",
            "time_published": "20240206T160300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2106.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.744043"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.104,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "TSVT",
                    "relevance_score": "0.205807",
                    "ticker_sentiment_score": "0.057832",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.051999",
                    "ticker_sentiment_score": "-0.073592",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.304428",
                    "ticker_sentiment_score": "0.064204",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.051999",
                    "ticker_sentiment_score": "-0.073592",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PBYI",
                    "relevance_score": "0.205807",
                    "ticker_sentiment_score": "0.142187",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Medicare now negotiating price of drug that costs $7,100 in US vs. $900 in Canada | Politics",
            "url": "https://www.cnn.com/2024/02/06/politics/medicare-drug-prices-eliquis-bernie-sanders/index.html",
            "time_published": "20240206T110000",
            "authors": [
                "Tami Luhby"
            ],
            "summary": "Medicare now negotiating price of drug that costs $7,100 in US vs. $900 in Canada ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/2024-01-29t162708z-699916914-rc2rr5a8hwzx-rtrmadp-3-health-usa-drugpricing.JPG?c=16x9&q=w_800,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.045088,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BMY",
                    "relevance_score": "0.081276",
                    "ticker_sentiment_score": "0.043728",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.16171",
                    "ticker_sentiment_score": "-0.002743",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Big oil's boring quarter was great news for investors",
            "url": "https://www.moneycontrol.com/news/opinion/big-oils-boring-quarter-was-great-news-for-investors-12205171.html",
            "time_published": "20240206T105855",
            "authors": [],
            "summary": "ExxonMobil Corp, Chevron Corp and Shell Plc all did in the fourth quarter what they'd promised: Start new oil and gas projects. cut costs. reward shareholders. Together, the Big Three returned more than $80 billion to shareholders last year, up from $78 billion in 2022 despite lower oil and gas ...",
            "banner_image": "https://images.moneycontrol.com/static-mcnews/2021/10/Zuckerberg-378x213.jpg?impolicy=website&width=168&height=118",
            "source": "Money Control",
            "category_within_source": "Economy",
            "source_domain": "www.moneycontrol.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.074568,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "EVR",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "0.075915",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVX",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "-0.026",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HES",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "0.002999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "0.043348",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RTX",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "0.043348",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "-0.026",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PXD",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "0.002999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RYDAF",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "-0.026",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson  ( NYSE:JNJ )  Lifted to Strong-Buy at StockNews.com",
            "url": "https://www.defenseworld.net/2024/02/06/johnson-johnson-nysejnj-lifted-to-strong-buy-at-stocknews-com.html",
            "time_published": "20240206T062643",
            "authors": [
                "Defense World Staff"
            ],
            "summary": "Johnson & Johnson ( NYSE:JNJ - Get Free Report ) was upgraded by research analysts at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a research note issued to investors on Tuesday.",
            "banner_image": "https://www.marketbeat.com/logos/johnson--johnson-logo-1200x675.png?v=20221020135923",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "www.defenseworld.net",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.752319"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.980716"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.253842,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "STT",
                    "relevance_score": "0.106541",
                    "ticker_sentiment_score": "0.2097",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.05339",
                    "ticker_sentiment_score": "0.020972",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.05339",
                    "ticker_sentiment_score": "0.020972",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DRVN",
                    "relevance_score": "0.05339",
                    "ticker_sentiment_score": "0.11403",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.159218",
                    "ticker_sentiment_score": "0.150757",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.796741",
                    "ticker_sentiment_score": "0.413641",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        }
    ]
}